University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2018

Strategies For Improving Epistasis Detection And Replication
Elizabeth Piette
University of Pennsylvania, elizabeth.piette@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Genetics Commons

Recommended Citation
Piette, Elizabeth, "Strategies For Improving Epistasis Detection And Replication" (2018). Publicly
Accessible Penn Dissertations. 3081.
https://repository.upenn.edu/edissertations/3081

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3081
For more information, please contact repository@pobox.upenn.edu.

Strategies For Improving Epistasis Detection And Replication
Abstract
Genome-wide association studies (GWAS) have been extensively critiqued for their perceived inability to
adequately elucidate the genetic underpinnings of complex disease. Of particular concern is “missing
heritability,” or the difference between the total estimated heritability of a phenotype and that explained by
GWAS-identified loci. There are numerous proposed explanations for this missing heritability, but a
frequently ignored and potentially vastly informative alternative explanation is the ubiquity of epistasis
underlying complex phenotypes.
Given our understanding of how biomolecules interact in networks and pathways, it is not unreasonable
to conclude that the effect of variation at individual genetic loci may non-additively depend on and should
be analyzed in the context of their interacting partners. It has been recognized for over a century that
deviation from expected Mendelian proportions can be explained by the interaction of multiple loci, and
the epistatic underpinnings of phenotypes in model organisms have been extensively experimentally
quantified. Therefore, the dearth of inspiring single locus GWAS hits for complex human phenotypes (and
the inconsistent replication of these between populations) should not be surprising, as one might expect
the joint effect of multiple perturbations to interacting partners within a functional biological module to be
more important than individual main effects.
Current methods for analyzing data from GWAS are not well-equipped to detect epistasis or replicate
significant interactions. The multiple testing burden associated with testing each pairwise interaction
quickly becomes nearly insurmountable with increasing numbers of loci. Statistical and machine learning
approaches that have worked well for other types of high-dimensional data are appealing and may be
useful for detecting epistasis, but potentially require tweaks to function appropriately. Biological
knowledge may also be leveraged to guide the search for epistasis candidates, but requires contextappropriate application (as, for example, two loci with significant main effects may not have a significant
interaction, and vice versa).
Rather than renouncing GWAS and the wealth of associated data that has been accumulated as a failure, I
propose the development of new techniques and incorporation of diverse data sources to analyze GWAS
data in an epistasis-centric framework.
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ABSTRACT
STRATEGIES FOR IMPROVING EPISTASIS DETECTION AND REPLICATION
Elizabeth Rachel Piette
Jason H. Moore

Genome-wide association studies (GWAS) have been extensively critiqued for their perceived
inability to adequately elucidate the genetic underpinnings of complex human phenotypes. Of
particular concern is “missing heritability,” or the difference between the total estimated heritability
of a phenotype and that explained by GWAS-identified loci. There are numerous proposed
explanations for this missing heritability, but a frequently ignored and potentially vastly informative
alternative explanation is the contribution of epistatic interactions underlying complex phenotypes.

Given our understanding of how biomolecules interact in networks and pathways, it is not
unreasonable to conclude that the effect of variation at individual genetic loci may non-additively
depend on and should be analyzed in the context of their interacting partners. It has been
recognized for over a century that deviation from expected Mendelian proportions can be
explained by the interaction of multiple loci, and the epistatic underpinnings of phenotypes in
model organisms have been extensively experimentally quantified. Therefore, the dearth of
inspiring single locus GWAS hits for complex human phenotypes (and the inconsistent replication
of these between populations) should not be surprising, as one might expect the joint effect of
multiple perturbations to interacting partners within a functional biological module to be more
impactful than individual main effects.

Current methods for analyzing GWAS data are not well-equipped to detect epistasis or replicate
significant interactions. The multiple testing burden associated with testing each pairwise
interaction quickly becomes nearly insurmountable with increasing numbers of loci. Statistical and
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machine learning approaches that have worked well for other types of high-dimensional data are
appealing and may be useful for detecting epistasis, but potentially require adaptations to suit
interaction analyses. Biological knowledge may also be leveraged to guide the search for
epistasis candidates, but requires context-appropriate application (as, for example, two loci with
significant main effects may not have a significant interaction, and vice versa).

Rather than renouncing GWAS and the wealth of associated data that has been accumulated as
a failure, I propose the development of new techniques and incorporation of diverse data sources
to analyze GWAS data in an epistasis-centric framework.
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ENHANCING THE REPRODUCIBILITY OF MACHINE LEARNING ANALYSES OF
GENOMIC DATA
Introduction
As the falling cost of DNA sequencing continues to outpace Moore’s Law, and new parallel and
distributed computing paradigms and technologies arise to manage the rapid accumulation of big
data, biomedical scientists are faced with new practical and analytical challenges including data
storage, merging heterogeneous data types from diverse sources, handling differentially missing
data, and more [87, 138]. The increasingly high-throughput nature of complex biomedical studies
pairs well with analysis via machine learning methods, which in general aim to automatically
improve performance of a task through experience [57, 71]. Machine learning has gained
incredible traction in the biomedical sciences and adjacent fields, evidenced by numerous fruitful
applications to diverse issues in genetics and genomics such as identifying binding sites from
sequences, functionally annotating hierarchical gene ontologies, building gene expression
networks for regulatory context, and more [78]. However, as machine learning methods continue
to increase in popularity and accessibility, it is critical to emphasize the importance of thoughtfully
considering how choices at each stage can impact a given analysis in the context of the unique
data challenges associated with big biomedical data. This review discusses reproducibility and
replicability in general before providing overviews of current issues in and methods for enhancing
reproducibility in the contexts of genome-wide association studies (GWAS) and machine learning,
both individually and in conjunction. Analyzing GWAS data beyond the traditional interrogation of
single-locus main effects to consider interactions or incorporate additional complementary data
sources may facilitate the discovery of new insights from pre-existing data. Finally, this review
concludes with a discussion of future directions for the field and suggestions for challenging
current paradigms in both genomics and machine learning to better integrate the two to promote
high-quality, reproducible science.
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Reproducibility vs. replicability
Variations on the terms “reproducibility” and “replicability” are used, sometimes interchangeably,
to broadly refer to the ability to achieve the same experimental results or arrive upon the same
conclusions given repetition of the same or similar experiment or analysis. This reproducibility is
generally accepted to be the defining property of robust scientific research and provides the basis
upon which future research depends. Despite the collective emphasis on the importance of
reproducibility/replicability in conducting research, which has been particularly acute in the
biomedical sciences in recent years given the explosion of data and the need to perform analyses
across bench lab conditions and computing environments, distinct scientific traditions have
proposed and embraced varying definitions over time of what these terms refer to and the relative
importance of the concepts they describe [53, 94, 107-9, 119]. An early definition of
reproducibility in the era of computational analyses orients us to an example of a major desired
quality of reproducible analysis, the ability to redraw a figure from the data and software provided
with a paper:

“A revolution in education and technology transfer follows from the marriage of word processing
and software command scripts. In this marriage an author attaches to every figure caption a
pushbutton or a name tag usable to recalculate the figure from all its data, parameters, and
programs. This provides a concrete definition of reproducibility in computationally oriented
research.” [38]

Over time, the definition of reproducibility has expanded and become more nuanced. The
following semantic distinctions can help contextualize these terms. However in common usage
these distinctions may be ignored, either term may refer to the same overarching concept, their
definitions may be flipped, or “reproducibility” may generally be preferred in computational
analyses and “replicability” in biological and other traditional experimental sciences [44, 95].

Reproducibility: Research may be considered reproducible if the data collected by the original
researcher and the analyses applied to that data (such as the software code used for data
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cleaning, statistical analyses, and figure generation) can be re-run by another individual to
produce the same numerical results, figures, etc. as in the original analysis.

Replicability: Research may be considered replicable if independently-performed data collection
and analyses lead to the same overall conclusion as the original research.

Therefore, replicability may be considered to be more robust than reproducibility in lending
support to a scientific finding, as it refers to independent confirmation from differing experimental
conditions. However, improving both replicability and reproducibility is necessary and desirable
for distinct reasons that feed into each other, especially in the current computational research
environment. For example, reproducing a certain experiment may be infeasible due to lack of
adequate computational resources; however, adhering to the principles of reproducible research
by sharing the code used in this analysis may allow an external researcher to analyze a different
data set with the same software to replicate the original finding.

Regardless of distinctions in definitions, in recent years the scientific communities across a
number of fields have acknowledged and struggled to address the reproducibility/replicability
crisis. Large-scale efforts to replicate prior experiments, analyses of experiments that have had
follow-up studies, and surveys of attempts to reproduce previously-conducted research have
found high rates of failure to replicate even one’s own experiments [4, 99, 110]. Explanations for
the reproducibility crisis are distributed across many steps and agents in the scientific process
with suggestions for improvements ranging from addressing the ways in which grants are
reviewed to how results are disseminated, but generally agreed upon top contributing factors
include “failure to adhere to good scientific practice and the desperation to publish or perish” [12].
The latter concern requires institutional changes outside the scope of this paper, although
advances in scientific data dissemination such as with journals that publish data descriptions and
negative results are an improvement. The era of high-throughput experiments has produced
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unprecedented volumes of data which may be analyzed in widely varying computational
environments, necessitating new definitions of “good scientific practice” for this research
landscape. In order to improve the reproducibility and replicability of machine learning analyses
of genomic data, it will be necessary to acknowledge contributing factors of failure to
reproduce/replicate in both of these fields and develop novel, integrative solutions.

Replicability of genome-wide association studies (GWAS)
GWAS aim to identify genetic variants associated with a phenotype, such as single nucleotide
polymorphisms that differ in frequency between cases and controls. Replication of a genotypephenotype association in another cohort is considered necessary to substantiate GWAS findings,
but there are numerous reasons why findings may fail to replicate despite a true association [33,
54]. The significance threshold for GWAS is Bonferonni-corrected for the estimated number of
independent tests of association being performed based on linkage disequilibrium, generally 5 x
10-8 for individuals of European descent and lower for other populations with greater genetic
diversity [70, 104]. Kraft et al. provide a helpful description of a Bayesian framework for
considering evidence of replicability, most importantly highlighting that “the probability that an
observed association truly exists in the sampled population depends not only on the observed pvalue for association, but also the power to detect the association (a function of minor allele
frequency, effect size and sample size), the prior probability that the tested variant is associated
with the trait under study, and the anticipated effect size” [74]. Therefore, at the widely-accepted
GWAS significance threshold, differences in minor allele frequency, effect size, and sample size
between the populations used in the discovery and replication cohorts may all contribute to failure
to replicate, but these factors are often not used to adjust the significance threshold accordingly.
Replicating GWAS findings of gene-gene interactions is even more difficult than for single
variants due to the increased multiple testing burden associated with naively testing each
combination of loci, but analyses that move beyond single variants are likely to become more
important in light of the growing disappointment in the amount of phenotypic heritability explained
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by individual loci and the acknowledgement of the distribution of risk across the genome [90, 96].
In addition to these statistical concerns, differences in genetic architecture and environmental
exposures between populations, differences in unmeasurable confounders between studies, or
technical sources of failure to replicate such as differences between genotyping platforms or
quality control protocols may all diminish the replicability of GWAS findings.

Methods for improving GWAS replicability
GWAS replication may be improved at the design stage when planning initial data collection and
analysis, or increasingly commonly in conducting secondary analyses that may combine preexisting GWAS data with other data sources. In the design stage, choosing a replication cohort
of a sufficient size that is of the same ancestry as the discovery cohort is generally recommended
to avoid the effects of population stratification, although effects that are replicated across different
populations may be considered more robust [91, 111]. Care should also be taken to ensure
consistent and accurate phenotyping between cohorts, as lack of phenotype harmonizing can
result in perceived poor replication due to making comparisons of associations with two
overlapping but distinct phenotypes; this is likewise a concern in performing meta-analysis of a
GWAS phenotype [13].

Methods for improving GWAS replication may be most fruitful if they aim to replicate network- or
pathway-based findings rather than single variant main effects [47, 67-9, 92, 105, 147]. Given the
complexity of the genome and of many common diseases/phenotypes, analysis of the cumulative
effects of numerous perturbations to a pathway may be more informative and replicable than the
effects of individual variants. These may also benefit from integration of additional data types
such as methylation or expression data, or incorporation of expert knowledge, to provide prior
knowledge or to use for dimensionality reduction to minimize the number of hypotheses being
tested [39, 61, 130]. Collecting and analyzing multiple sources of data in conjunction is becoming
increasingly feasible, and seems a logical next step for attempting to explain more of the genetic
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variation of a trait than GWAS alone. Performing secondary analyses that repurpose data from
multiple sources, which has been both maligned and praised as “research parasitism”, is likely to
become increasingly popular given the modern emphasis on data sharing and decreasing
financial barriers to accessing adequate computational resources [9, 85, 118]. Improving the
methods by which diverse data types are consolidated, the ways in which machine learning
methods and parameters are chosen to suit the data and shape the analytic pipeline, and good
software and computational environment sharing practices will shape the future of genomic
analyses, and thoughtful guidelines surrounding each choice will be necessary to prevent the
propagation of errors.

Reproducibility of machine learning analyses
As lack of replicability across many traditional scientific fields has reached the point of crisis,
improving the reproducibility of computational analyses has concurrently emerged as a solution
for minimizing or eliminating many of the preventable inconsistencies that hinder replicable
research [43, 125]. Version control repositories and code hosting platforms such as GitHub
enable sharing exact code and data sets used for analyses, reducing the need for reimplementation of algorithms to solve problems that have already been well-realized and
improving the ability to suggest and disseminate new versions [84]. Using tools such as Docker
that consolidate entire computational environments, or sharing a cloud instance between
collaborators at multiple research sites rather than performing multiple individual analyses with
different high performance clusters, removes concerns regarding software versioning and
inconsistent analytic pipelines or quality control steps between sites [32, 45, 64, 93]. These are
particularly relevant to GWAS analyses because seemingly minor differences in data preprocessing or model training may result in different top hits.

Methods for improving machine learning analysis reproducibility
Reproducibility of computational analyses is largely thought of in terms of implementing the same
exact analysis on the same data in the same computational environment, but if improving
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replicability of GWAS findings is the goal, it may be as important to consider how a machine
learning analysis of one data set may need to be altered to replicate a finding in another cohort,
which requires understanding how the choices made in a given analysis can impact the result.
For example, a discovery data set may have observations missing at random, and a replication
data set may have observations missing not at random in a modelable way, which could warrant
applying different imputation techniques. In this sense, reproducibility may be seen as a way to
help facilitate future replication. The following section documents how choices the researcher
may make at each stage of a typical machine learning analysis may impact the ultimate analytic
conclusion. Figure 1 provides an overview of a generic supervised machine learning workflow.
Although accompanied by examples of applications to GWAS analysis or the biomedical sciences
more broadly, these concerns are overarching and may be translatable across many research
domains wherever large, complex data is analyzed.

Figure 1. A generic supervised machine learning analysis. Machine learning workflows are often
iterative with interrelated stages, so comprehensive or rigid definitions are unsuitable. For
example, the researcher may already have a particular algorithm in mind and perform imputation
to ensure the data is in a suitable format free of missingness prior to feature selection.
Alternatively, the researcher may perform feature selection prior to data pre-processing if
unimputed variables with low missingness are considered higher quality or more potentially
informative.
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Choosing between algorithms
Algorithm choice may be driven by a combination of the overarching goals of the analysis,
number and structure of predictors, presence of interactions or non-linearity, time and
computational constraints, and perhaps at the most basic level the availability of labeled data.
Machine learning approaches are typically classified as either supervised or unsupervised
depending upon whether the learner uses labeled training data, although there also exist semisupervised approaches in which a subset of the data is labeled and the rest remains unlabeled
and reinforcement learning approaches in which [146]. In a typical supervised analysis, an
algorithm is applied to a portion of a data set designated for use in the “training” stage of a
classification or regression task, after which the model derived from this training is applied to held
out data in the “testing” stage and performance is evaluated. Ideally the model will be
generalizable enough that it reasonably captures underlying trends in the data and will perform
well for data that it has not encountered during training, avoiding the “overfitting” that results from
overly complex models or irrelevant predictors that pick up on the noise inherent in the training
data [50]. Some classes of algorithms have become largely acknowledged as being particularly
well-suited to certain applications based on complimentary characteristics of the algorithm and
data, such as support vector machines for functional classification of genes from gene expression
data [25]. Unsupervised analyses attempt to uncover structure in data lacking labels, for example
k-means clustering of gene expression data to identify novel tumor subtypes with clinical
significance [128]. A number of helpful sources exist that provide guidance regarding algorithm
selection considering the analytic goal, computational burden, number of features, data
sparseness, etc. [48, 121].

Ensemble approaches
Considering the “no free lunch” theorem that essentially posits no single algorithm will be optimal
for all applications, ensemble approaches in machine learning that aggregate the decisions of
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multiple predictors are appealing [42, 139]. Early forays into model combination in the statistical
and especially economics fields laid the basis for the development of Bayesian model averaging,
in which the posterior distribution of each potential model is weighted by its posterior model
probability [6, 8, 63, 77]. Although this is an appealing way to circumvent the uncertainty
associated with model specification, it may be computationally expensive or infeasible to
implement as the number of models increases, and estimating the posterior probability can also
be a challenge. See Yeung et al. for an implementation of Bayesian model averaging in the
context of gene selection and classification of microarray data [143]. Bagging, short for bootstrap
aggregating, is a popular ensemble approach in which new training sets are generated via draws
with replacement from the original training set and models are fitted to each of these then
subsequently aggregated via averaging or voting [22]. Dudoit and Fridlyand describe a combined
bagged clustering procedure for identifying tumor subtypes from gene expression profiles [46].
Boosting is another popular ensemble approach in which many weak classifiers are iteratively
learned and weighted relative to their performance to create a single strong one, for example via
their linear combination [21, 120]. Niu et al apply AdaBoost, one of the most popular boosting
algorithms, to a protein structural class prediction problem [101].

Hyperparameter optimization
The performance of machine learning methods that require hyperparameters, which are
parameters of the algorithm itself assigned before any training takes place (such as number of
trees in a random forest or layers in a neural network), may be largely impacted by their choice
[17, 127]. Popular hyperparameter optimization algorithms include grid search and Bayesian
optimization. A grid search, or parameter sweep, is an exhaustive search of the combinations of
hyperparameter values within user-defined bounds. The hyperparameter combination that best
optimizes a user-specified loss function, for example prediction accuracy on held-out testing data,
is chosen. Grid search may be computationally expensive due to its exhaustiveness, which

9

random search circumvents via instead sampling a subset of the hyperparameter combination
space, but may be readily parallelized [17]. Grid search may be particularly relevant to GWAS
simulation applications that aim to characterize and compare performances with machine learning
methods across a range of scenarios in which factors such as minor allele frequency, heritability,
prevalence, etc. are varied. Bayesian optimization assigns a (generally Gaussian) prior to the loss
function, uses an acquisition function to determine where to sample from in the loss function, then
updates the posterior to determine the next sampling location [124, 23]. The researcher may
alternatively define more meaningful prior distributions that incorporate additional meta-data
about the experiments or data sets. Since Bayesian optimization does not require searching the
entire hyperparameter space, it also reduces the computational resources required.

Data pre-processing
Multiple iterations of pre-processing may be necessary prior to conducting a machine learning
analysis in order to render the data into an appropriate format for the algorithm of interest, reduce
dimensionality, combine multiple disparate sources of data, etc. Algorithms often require data
sets to be free of missingness in order to run, in which case the researcher must consider the
type of missingness and decide upon a strategy for addressing missing observations. Little and
Rubin provide a definitive guide to handling missing data [81]. Even if the algorithm
implementation in question includes an embedded approach to produce a complete data set, or
alternatively the researcher has decided to choose an approach that allows for missingness and
avoids imputation, it is important to consider the pattern and mechanism of the missingness and
the biases specific to the experimental conditions that produced said data. Pre-processing in
GWAS requires multiple steps of quality control to remove poor quality samples, SNPs, and batch
effects, and different threshold choices at each step and even the order in which the steps are
performed may all impact the resulting top hits and may be difficult to coordinate even between
sites working on the same data set [129]. A Jupyter notebook that allows users to execute and

10

supervise an automated cloud-based quality control pipeline can both allow for quality control
harmonization between sites, and for the alteration and sharing of pipelines to better suit
individual analytic needs. Data pre-processing to incorporate multiple heterogeneous data
sources may be an even greater challenge, requiring pre-processing not only of each data source
individually, but in consideration of whether and how data will be merged and analyzed [114].

Feature selection
Feature selection is often a critical component of analyses of data sets containing large numbers
of variables, and can help improve predictions by utilizing the most informative features, reduce
the time and computational resources needed to run an algorithm, enhance interpretability and
visualization, and avoid the “curse of dimensionality” [14]. Many commonly-used methods are
based on either filters that rank variables based on intrinsic data qualities such as correlation with
other variables, wrappers that assess groups of variables as they optimize accuracy in a
predictive model, or combined and embedded methods [55, 65, 117]. Feature selection may be
impacted by pre-processing so it may be beneficial to consider how the two may play in to each
other, for example by weighting variable rankings according to a data quality score reflective of
missingness. Feature selection is incredibly pertinent to GWAS analyses in order to circumvent
the high multiple testing burden. SNPinfo is an example of a SNP selection tool that incorporates
functional predictions, linkage disequilibrium, and GWAS results to select relatively small
numbers of SNPs for GWAS [140]. Cantor et al. provide a review of how meta-analysis, epistasis
testing, and pathway analysis can be used to prioritize GWAS results [28].

Cross validation
Implementing a supervised machine learning analysis generally constitutes training on a subset
of the data and evaluating performance on a held-out test set, which allows for unbiased
evaluation of a model’s performance and helps avoid overfitting [112]. The simple hold-out
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method is a popular way to choose training and testing partitions by randomly dividing the data
into two non-overlapping sets. Also popular are the number of variations on k-fold cross
validation, in which the data is divided into k subsets, rounds of training are performed on each
subset and tested on all remaining data, and performance is estimated by averaging across all
rounds . In addition to choices regarding how to partition the data and how many folds and/or
repetitions should be used, the cross validation method chosen should be appropriate for the data
and application particularly regarding desires to minimize bias or variance [133]. For example the
repeated k-fold cross validation method is biased by overlap between training and testing sets.
Additionally, bias is introduced by performing feature selection or other classifier training or
parameter selection outside of the cross validation procedure; these must be performed
separately within each round. Cross validation can be affected by class imbalance with regard to
the dependent or independent variables, and re-weighting and re-sampling methods have been
developed to address the inconsistencies that may arise because of this [5, 24]. In GWAS
analyses, consistent cross validation results from any number of supervised algorithms may be
used to select subsets of SNPs or interaction models [11, 60].

Interpretation
The choice of algorithm and its associated assumptions can greatly impact interpretability of
results from machine learning analyses. The enduring popularity of linear models despite the
potential accuracy improvement that may be gained from applying more complicated “black box”
models may be partially ascribed to their ease of interpretation. Therefore, the researcher should
consider whether the aim of an analysis is solely to maximize accuracy or some other
performance measure, or if meaningful knowledge concerning the model features is desired. The
gap in our current ability to apply some machine learning methods very accurately yet fail to be
able to adequately interpret them may be reduced by improvements in the intersection of
dimensionality reduction and visualization techniques [135].
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Conclusion and future directions
Improving the reproducibility of machine learning analyses of genomic data will require thorough,
rigorous interrogation of how decisions at each stage of a machine learning analysis impacts
results across a range of data types with varying biases to ensure that analyses are paired with
the most appropriate choices of algorithm, hyperparameters, meaningful features, etc. Large
benchmarking efforts that explore which machine learning methods are best suited to data sets of
varying complexity, size, numbers of features, and feature types are already under way [103].
Extending this paradigm to benchmark as many publicly available genomics data sets as possible
can improve the basis upon which artificial intelligence methods can suggest data analysis
pairings [102]. Improved standardization of data collection tools to feed directly into analysis may
help further streamline the process overall and help reduce careless errors related to data entry
or transfer. The future of genomic data analysis is likely to be increasingly integrative, with
GWAS as one of many data sources that must be processed and linked to be used in machine
learning analyses.
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IMPROVING THE REPRODUCIBILITY OF GENETIC ASSOCIATION RESULTS USING
GENOTYPE RESAMPLING METHODS

Introduction
Replication is the gold standard for substantiating the validity of results across the spectrum of
biological sciences, and is a cornerstone of rigorous hypothesis-driven research. In this era of big
data and complex, computationally-intensive research, true replication may be impossible or
infeasible, and reproducibility of analyses is a proximate concern [107]. Both replication and
reproducibility are beset with challenges associated with a diversity of issues ranging from data
access and storage, to availability of requisite computational resources, to thoughtfully
implemented, high-quality code, all in the context of a constantly shifting field with high software,
hardware, and ideological turnover. While advances such as portable, versioned workflows for
computational environments and proposed statistical frameworks for defining replication and
reproducibility themselves are addressing some of these issues, certain roadblocks to replication
and reproducibility have yet to be resolved and may continue to remain impractical and
inaccessible to the average researcher, such as for the analysis of data sets involving millions of
parameters, multiple processers, and finite time [19, 75, 106, 116].
In the context of genome-wide association studies, failure to replicate previously-observed
findings in a second population may be attributable to a combination of statistical and biological
factors. Investigating the genetic underpinnings of complex diseases presents a special challenge
given the evidence for multi-locus or network-based models of disease and the increased
multiple-testing burden associated with fitting interaction models over single-locus models [90].
This is in addition to considerations of the heterogeneity of disease etiology, underlying genetic
architecture, and other confounding factors that vary across populations. In this study, we explore
epistatic interactions as a case study of a phenomenon that may be inherently difficult to
replicate, and attempt to recapitulate the power to detect epistatic interactions between single
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nucleotide polymorphisms (SNPs) in two populations with differing minor allele frequencies
(MAFs).
Epistasis, briefly defined as interactions between genetic loci that non-additively contribute to
phenotype, is suspected to be both ubiquitously implicated in susceptibility to non-Mendelian
disease and difficult to detect and replicate [96]. Resampling populations so that they appear
more similar for the genotypes of interest may allow us to compare them in a more meaningful
way. In this study, we propose a method for improving detection of epistatic SNP-SNP
interactions between genome-wide association study (GWAS) data sets with differing minor allele
frequencies for the SNPs of interest via resampling by genotype such that genotypes that are
underrepresented in the replication population relative to the discovery population are
oversampled, and genotypes that are overrepresented are undersampled. We substantiate the
efficacy of this method via simulations. Application of this method may help inform scenarios in
which findings of interest with potential functional significance from a discovery population sample
fail to reach statistical significance in a replication population sample.

Data sets and methods
The following subsections describe our methods workflow (refer to Fig. 1 for accompanying
graphical abstract). Briefly, we begin with data set simulation for a selection of models with
varying penetrance functions, minor allele frequencies for two SNPs, heritabilities, and
prevalences. Then, we use the discovery penetrance tables to generate replication data with the
same underlying penetrances but differing minor allele frequencies. Next, we analyze the SNPSNP interactions for all discovery scenarios by calculating the p-value for the likelihood ratio test
comparing the logistic regression models with and without the interaction between the two SNPs,
and estimate power to detect the interaction over 1000 simulations. Replication data sets are
resampled to match the genotype proportions of their relative discovery data sets, and interaction
analysis and power estimation is performed again post-resampling. We also test negative
simulations to address the possibility of erroneously significant interactions – sample data sets

15

with significant p-values for the interaction, despite being drawn from an underlying population
without a significant interaction.

Figure 3. Graphical abstract (a) A SNP-SNP interaction results in 9 genotypes (b) In Population
A, the SNP1 minor allele frequency is 0.5, and the SNP2 minor allele frequency is also 0.5. A
GWAS of Population A reveals a significant association between the ‘11’ genotype and disease
status. (c) Replication of this interaction is sought in Population B, and another GWAS is
performed. However, in Population B, the SNP1 minor allele frequency is 0.1, and the SNP2
minor allele frequency is 0.5, so the relative distribution of genotypes is different. A GWAS of
Population B does not reveal a significant association between the ‘11’ genotype and disease
status, despite the same penetrance for genotype ‘11’ in Population B and in Population A, due to
the low minor allele frequency of SNP1/low prevalence of genotype ‘11’ in Population B. (d)
Resampling by genotype allows us to observe what our Population B sample would look like if the
minor allele frequencies for SNP1 and SNP2 were the same as in Population A. Performing
resampling numerous times allows for an empirical estimation of power to detect a significant
interaction.
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Discovery data set simulation
Penetrance functions and data sets for eight discovery scenarios were generated using
GAMETES, an algorithm and software package that facilitates generation of complex epistatic
models and data sets based upon these models [131]. Our test parameters (Table 1) included
minor allele frequencies of 0.5 and 0.5 or 0.1 and 0.1 for two SNPs, heritabilities of 0.05 or 0.005,
and prevalences of 0.5 or 0.1. Case-control data sets of size 2,000 and 4,000 were tested, and all
simulation scenarios were replicated 1,000 times.

Replication data set simulation
Replication data sets were generated using the discovery penetrance tables to create data sets
with the same underlying penetrances but differing minor allele frequencies. First, each simulated
individual is assigned a value of 0, 1, or 2 for SNP 1 genotypes, with probabilities corresponding
to genotype frequencies in Hardy-Weinberg equilibrium. This is repeated for SNP 2. Then, each
simulated individual is assigned their case-control status based on their assigned values for
SNP1 and SNP2 and the corresponding penetrance for that genotype from the discovery
penetrance function. All discovery scenarios had corresponding replication scenarios with all twoSNP minor allele frequency combinations of {0.5, 0.4, 0.3, 0.2, 0.1}. We also include a finer
resolution version replicating the discovery scenario with minor allele frequencies of 0.5 and 0.5,
heritability of 0.005, and prevalence of 0.5 (Model 1 from Table 1) with replication SNP1 minor
allele frequency fixed at 0.5, and SNP2 minor allele frequency from 0.5 to 0.01 by 0.01. 1,000
data sets of sizes 2,000 and 4,000 were generated for each replication scenario.
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Table 4. Discovery data set simulation parameters: minor allele frequencies, heritabililties,
prevalences, and penetrance tables used to generate discovery data
Model 1
0.5
0.5
0.005
0.5

SNP1 MAF:
SNP2 MAF:
Heritability:
Prevalence:
Penetrance:

0.475
0.524
0.476

0.469
0.516
0.498
Model 3
0.5
0.5
0.005
0.1

0.586
0.443
0.528

0.495
0.449
0.608

0.646
0.451
0.451
Model 4
0.5
0.5
0.05
0.1

0.214
0.649
0.498

0.145
0.065
0.125

0.092
0.110
0.088
Model 5
0.1
0.1
0.005
0.5

0.071
0.115
0.098

0.130
0.081
0.108

0.105
0.145
0.006
Model 6
0.1
0.1
0.05
0.5

0.061
0.029
0.281

0.507
0.467
0.548

0.475
0.624
0.274
Model 7
0.1
0.1
0.005
0.1

0.407
0.906
0.692

0.524
0.387
0.604

0.395
0.999
0.033
Model 8
0.1
0.1
0.05
0.1

0.458
0.689
0.462

0.097
0.117
0.035

0.113
0.024
0.391

0.102
0.093
0.092

0.115
0.031
0.118

0.036
0.394
0.017

0.029
0.417
0.128

SNP1 MAF:
SNP2 MAF:
Heritability:
Prevalence:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Heritability:
Prevalence:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Heritability:
Prevalence:
Penetrance:

Model 2
0.5
0.5
0.05
0.5
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Interaction analysis
For all replicates of all discovery scenarios, we calculated p-values for the likelihood ratio test
comparing the logistic regression models with and without the interaction term for the two SNPs
of interest, where the two models being compared are:

(1)

And
(2)

Where P(case) is a binary indicator of disease status, SNP1 and SNP2 are categorical variables
with values of 0, 1, or 2 corresponding to homozygous dominant, heterozygous, or homozygous
recessive genotypes, and SNP1*SNP2={00, 01, 02, 10, 11, 12, 20, 21, 22} is the Cartesian
product of SNP1 and SNP2.

Power estimation
For the purpose of our power calculations we define power not in the traditional statistical sense,
but rather as an empirical measure of the number of successes (where success is defined as a pvalue of less than 0.05 for the likelihood ratio test comparing the two models above) out of the
total number of simulated replication data sets for each scenario.

Replication data set resampling
All replication data sets were resampled to match the genotype proportions of their corresponding
discovery data sets by taking a random sample with replacement of the desired number of
observations for each genotype, as follows. First, calculate desired genotype proportions from the
crossproduct of discovery SNP1 proportions and discovery SNP2 proportions. Then, multiply
desired genotype proportions by data set size to obtain the desired number of observations per
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genotype (if the discovery and replication data sets are the same size, there are simply equal
numbers of individuals per SNP-SNP genotype combination, otherwise, they are proportionate).
Next, ensure that there is at least one case and one control per genotype, and if not, add single
pseudo-observations to ensure non-zero case and control sampling probabilities. Finally, for each
genotype, take a random sample with replacement to the desired number of observations. The
resampled replication data set is the composite of these samples by genotype. The following
pseudocode outlines the resampling method.

INITIALIZE data frame to store resampled data set
FOR each SNP-SNP genotype
SUBSET all observations of the genotype from the replication data set
IF there are no case observations in this subset THEN
APPEND a single case pseudo observation
IF there are no control observations in this subset THEN
APPEND a single control pseudo observation
SAMPLE with replacement to size proportionate to discovery genotype
APPEND sample to resampled data set

Negative simulation methods
Negative simulation data sets were generated such that the SNP-SNP interaction is significant in
the underlying discovery population but not the replication population. We generated 1000
discovery data sets of size 4000 with minor allele frequencies of 0.5 and 0.5 for the interacting
SNPs with penetrances of 0.5 for 8 of the 9 SNP-SNP genotypes and a penetrance of 0.9 for the
SNP-SNP genotype where both SNPs have two doses of the minor allele. We next generated
15,000 replication data sets, 1000 each of the 15 two-SNP minor allele frequency combinations of
{0.5, 0.4, 0.3, 0.2, 0.1}. All replication data sets were generated with a penetrance of 0.5 for all
SNP-SNP genotypes, that is, none of the interacting SNP-SNP genotype combinations are
significant. All power calculations for the discovery and replication data sets are estimated as
described above in the “Power Estimation” section, and resampling of the replication data sets
that were false positives was performed as described in “Replication Data set Resampling”.
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Results
Positive simulation results
We found that performing resampling of the replication data sets generally resulted in better or
comparable power to detect the interaction between SNP1 and SNP2 compared to the power to
detect the interaction using the unadjusted replication data sets. Figure 2 illustrates a scenario in
which the minor allele frequencies of both SNP1 and SNP2 are 0.5 in the discovery data set, and
in the replication data sets the SNP1 MAF is held constant at 0.5 and only SNP2 is varied from
0.5 to 0.01 by 0.01 increments. There is increasing divergence of the unadjusted replication
power to detect the interaction as the minor allele frequency of SNP2 decreases. Resampling
results in better power to detect the interaction, with the worst performance observed for
scenarios with the greatest difference between discovery and replication SNP2 minor allele
frequency.

Figure 4. Detection of a SNP-SNP interaction in unadjusted versus resampled replication data
sets. Model 1: discovery SNP1 MAF = 0.5, SNP2 MAF = 0.5. Replication SNP1 MAF = 0.05,
SNP2 MAF from 0.5 to 0.01 by 0.01. Heritability = 0.005 and prevalence = 0.5 for all discovery
and replication data sets.
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Likewise, Figure 3 illustrates a comparable trend when both replication SNP1 and SNP2 minor
allele frequencies are varied, with increasingly poor power to detect the interaction for unadjusted
replication data sets with SNP1 and SNP2 minor allele frequencies that are more distant from
those of the discovery data set. Once again, we estimate replication powers to detect the
interaction that are much improved after performing resampling. Table 2 tabulates the pre- and
post-resampling powers for the interaction for the remainder of our test models.

Figure 5. Detection of a SNP-SNP interaction in unadjusted versus resampled replication data
sets. Model 1: discovery SNP1 MAF = 0.5, SNP2 MAF = 0.5. Replication SNP1 MAF and SNP2
MAF combinations from 0.5 to 0.1 by 0.1. Heritability = 0.005 and prevalence = 0.5 for all
discovery and replication data sets.

Negative simulation results
We developed a negative simulation in order to both establish that our simulated data sets have a
realistic false positive rate, and to investigate the factors that contribute to why data sets may fail
to recapitulate the true underlying population significance of an interaction following application of
our resampling method. In the vast majority of cases, if a SNP-SNP interaction is significant in a
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discovery population and not significant in a replication population, we will indeed observe
respectively significant and non-significant p-values for the likelihood ratio test comparing the
logistic regression models with and without the interaction in samples taken from these
populations. However, samples do not always provide good representations of the underlying
population. For a p-value cutoff of 0.05, we expect a 5% false positive rate, and indeed, 747 of
the 15,000 simulated replication data sets (4.98%) yielded false positives (e.g. the data set
yielded a significant p-value for the likelihood ratio test, even though the interaction was truly nonsignificant). We also expect the majority of these false positives to be unsuitable candidates for
application of our resampling method because erroneous significance is driven by genotypes with
so few observations that the sample penetrance is not representative of that of the underlying
population, which is what we observe - 694 of the 747 false positives (92.9%) remain false
positives after resampling.
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Table 5. Pre- and post-resampling power (successes per 1000 simulated data sets) summary for
all SNP-SNP minor allele frequency combinations for all models. See Table 1 for data set
parameters by model number.
Model #
(Pre-resampling power,
Post-resampling power)
SNP1
MAF

SNP2
MAF
0.5
0.4

0.5

0.3
0.2
0.1
0.4
0.3

0.4
0.2
0.1
0.3
0.3

0.2
0.1
0.2

0.2
0.1
0.1

0.1

1

2

3

4

5

6

7

8

962
932
893
921
684
916
375
890
136
917

1000
1000
1000
1000
1000
1000
1000
1000
1000
1000

969
944
989
967
984
966
988
977
857
958

1000
1000
1000
1000
1000
1000
1000
1000
999
1000

1000
1000
1000
1000
1000
1000
1000
1000
1000
1000

1000
1000
1000
1000
1000
999
1000
1000
1000
1000

938
1000
934
1000
951
1000
946
1000
944
1000

1000
1000
1000
1000
1000
1000
1000
1000
1000
1000

923
935
753
929
439
908
141
922

1000
1000
1000
1000
1000
1000
998
1000

993
971
994
965
976
984
850
973

1000
1000
1000
1000
1000
1000
999
1000

1000
1000
1000
1000
1000
1000
1000
1000

1000
1000
1000
999
1000
1000
1000
1000

941
1000
950
1000
953
1000
952
999

1000
1000
1000
1000
1000
1000
1000
1000

774
937
451
947
117
948

1000
1000
1000
1000
999
1000

991
975
978
971
807
991

1000
1000
1000
1000
967
1000

1000
1000
1000
1000
1000
1000

1000
1000
1000
1000
1000
1000

942
1000
967
1000
947
999

1000
1000
1000
1000
1000
1000

377
959
105
928

1000
1000
989
1000

958
988
729
997

971
1000
746
1000

1000
1000
998
1000

1000
1000
1000
1000

941
1000
950
999

999
1000
1000
1000

106
965

903
1000

520
998

315
1000

964
1000

1000
1000

934
920

999
1000
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Figure 6. Distributions of penetrances by SNP-SNP genotype. Note that 48 of the data sets that
did not successfully resample had zero observations for the 22 genotype (Part I), so the density
reflects only those data sets for which we can calculate penetrances.
Comparing the penetrances and number of observations by SNP-SNP genotype provides insight
into the factors that render our resampling method inappropriate. In Figure 4 one may observe
that, while the mean penetrances for each genotype are comparable and centered around the
expected value of 0.5 for those that do and do not successfully recapitulate the initial significance
of the interaction following resampling, the variances differ significantly, particularly for the rarer
genotypes. Table 3 provides a summary of the penetrance distributions and the number of
observations by genotype. Recall that the minor allele frequencies of the two SNPs in the
replication data sets are both 0.1, so the SNP-SNP genotype where both SNPs have two doses
of the minor allele is quite rare, and in some cases, replication data sets completely lacked
observations for this genotype. Looking at this genotype in particular (Figure 4, part I), the
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“unsuccessful” density is quite broad and flat, which stands to reason - since there are generally
so few observations of this genotype, a population sample can be quite unrepresentative of the
underlying population. Small perturbations in the observed number of cases per genotype can
greatly skew the perceived significance of an interaction when the number of observations per
genotype is quite low. In order to make reasonable inferences on the significance of an
interaction, we recommend ensuring an adequate number of observations for the lowest
frequency genotypes. This resampling method is only applicable if the underlying penetrances by
genotype are reasonable approximations of the true population penetrances; our method simply
provides a power boost for situations where we don't have enough observations of certain
genotypes relative to others, but the observations we do have must be representative draws from
the underlying population.

Table 3. Penetrance distribution summary statistics and number of observations, by SNP-SNP
genotype, for data sets that successfully versus unsuccessfully resample
Successfully resampled
(n=53)
SNP-SNP
genotype
00
01
02
10
11
12
20
21
22

Mean
penetrance
(SD)
0.502
(0.036)
0.498
(0.038)
0.496
(0.063)
0.497
(0.025)
0.495
(0.023)
0.503
(0.037)
0.495
(0.036)
0.512
(0.045)
0.496
(0.053)

Median
observations
(min, max)
489
(232, 1244)
489
(179, 817)
162
(9, 269)
733
(460, 1610)
920
(348, 1022)
290
(20, 534)
330
(180, 815)
42
(106, 537)
108
(9, 263)

Unsuccessfully resampled
(n=694)
Mean
penetrance
(SD)
0.499
(0.023)
0.502
(0.034)
0.500
(0.122)
0.502
(0.020)
0.498
(0.033)
0.498
(0.123)
0.500
(0.046)
0.505
(0.095)
0.501
(0.194)

26

Median
observations
(min, max)
904
(223, 2679)
478
(154, 917)
78
(5, 284)
996
(454, 1684)
618
(115, 1047)
77
(4, 547)
309
(21, 850)
189
(2, 548)
25
(0, 281)

Discussion
This study critiques the validity of replication as the gold standard for substantiating GWAS hits,
and proposes the exploration of alternative approaches that consider how differences in factors
such as minor allele frequency can modulate the observed significance of SNP-SNP interactions.
This may expand the usefulness of data that is already collected, which can in turn better direct
our resources to future studies that will be most fruitful.
For the purposes of our positive simulations, we tested an exploratory range of heritabilities,
prevalences, and sample sizes, but did not explore a wide range of differences in these
parameters between populations. Small differences in minor allele frequency between discovery
and replication data sets can greatly reduce the power to detect main effects, and the ability to
detect this may differ by heritability, so it seems plausible that the ability to detect interactions
may follow similar and possibly even more pronounced trends [54]. Future investigation into the
potential joint effects of these parameters may yield further insight into the factors that affect our
ability to detect and assess interactions in diverse populations, and subsequently direct study
design to better control for these differences. Similarly, more negative simulations should be
performed that systematically cover a range of scenarios to illuminate the conditions under which
we can reliably regain power to detect interactions in replication studies; our negative simulations
do not establish guidelines for across the entire space of observable population parameters.
Additional future analyses may also aim to demonstrate that shifts in interaction significance
following resampling can alter which ones are selected for model inclusion, thereby modulating
our ability to predict case-control status. Investigating shifts in variable inclusion following
resampling is likely to yield interesting biological insight. Indeed, the future of extracting
meaningful findings from GWAS is likely to be driven by investigating SNPs that are initially
identified either based on expert knowledge or via bioinformatics methods incorporating prior
assumptions, including hierarchical models that consider groups of SNPs and their functional
relationships and interactions, in order to bypass the extreme prejudice of multiple testing burden
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[27, 97, 141]. Furthermore, the genome-wide significance level is unlikely to be an appropriate
one-size-fits-all cutoff for multiple reasons, including evidence for the successful replication of
borderline statistically significant genotype-phenotype associations [104]. It also stands to reason
that diverse populations with different genetic architectures may require variable significance
cutoffs that better reflect their patterns of linkage disequilibrium; hopefully, the increasing quantity
of genotyped diverse populations will result in more pertinent high-quality reference genomes that
will better enable identifying and replicating genetic associations between populations, enabling
more accurate comparison of populations in the context of structural differences between diverse
genomes [36, 115].
As new computational methods for GWAS present solutions to the various challenges associated
with the accumulation of vast amounts of ever denser genetic data, and is mutually reinforced
with increasing integration with clinical and epidemiological data, it is important to keep sight of
the end goal of practical application of this knowledge to the betterment of both population health
and personalized medicine. As such, the ultimate takeaway from this study should be that the
purpose of resampling is to identify potential candidates for further biological validation, with the
intention of using these findings to reduce structural inequalities in health and medicine.
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IMPROVING MACHINE LEARNING REPRODUCIBILITY IN GENETIC ASSOCIATION
STUDIES WITH PROPORTIONAL INSTANCE CROSS VALIDATION (PICV)
Background
Genome-wide association studies (GWAS) have been frequently critiqued for failing to explain the
“missing heritability” of complex disease in terms of single-locus main effects [89, 137]. In addition
to interrogating the contributions of rare variants, non-coding regions, structural variation, etc., a
logical reactionary paradigm to embrace involves revisiting heritability estimates to consider the
effect of interactions and developing approaches that acknowledge that loci do not exist in
isolation but rather act in complex networks of interacting partners in the dynamic, threedimensional genome and in tissue-specific and environmental context [39, 40, 79, 148]. Utilizing
pre-existing GWAS data to test a curated set of potentially biologically-relevant interactions, such
as those identified as being plausible via expert knowledge, integrating data from gene set
enrichment analyses, chromatin capture experiments, co-expression data sets, etc. provides a
way to overcome the multiple testing burden of naively testing every possible interaction and
motivates future bench science experimentation [26, 114]. Accordingly, machine learning
methods are appealing for the analysis of this big, complex data, and have been applied to
diverse problems and data types across the biological sciences [76, 78]. However, machine
learning should not be viewed as a panacea that can be readily applied to all genomics problems.
Beyond concerns regarding model choice and interpretability, there are numerous reasons why
valid biological interactions may fail to appear statistically significant and vice versa [54, 97-8].
Therefore, typical machine learning tools, techniques, and standards from other fields may need
tweaking to be appropriate for use in genomics considering the unique biases in generating
genomic data sets, the structure of the genome, the validity of model assumptions, etc.
Improving the reproducibility of machine learning analyses of genomic data will require
methodological and analytic advances from not only both the computational and wet laboratory
sides, but also their consideration in conjunction with each other as a greater whole. Sharing
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data publicly for secondary analyses, writing open-source code in executable notebook format,
and using container and cloud services all contribute to a culture of reproducibility that enhances
the capacity for integrative and innovative computational analyses [10, 72, 85, 93]. Likewise,
thoughtfully interrogating methodological, environmental, and other determinants of
inconsistencies in bench experimentation results lends robustness to findings, and this greater
understanding of sources of variation can in itself lead to worthwhile new hypotheses [62]. Ideally,
technological supports such as mobile applications for data collection will increasingly allow for
recording more complete and consistent data in a format that can be seamlessly analyzed with
software tools developed or modified to consider the unique intricacies of the data at hand [110].
Epistasis, or the non-additive interaction between genotypes to produce phenotype, is difficult to
detect statistically but is of biological interest in light of a multifactorial view of disease [29, 90,
96]. This study is motivated by poor cross-validation performance observed for epistasis data sets
with an interaction between two single nucleotide polymorphisms (SNPs). Cross validation is a
widely-used standard for evaluating the performance of a machine learning analysis in which the
data is split into training and testing partitions, a model is fit using the training set, and its
performance is evaluated on predicting the classes of the held out test set observations [3].
Typically the overall data set is split such that the resultant training and testing partitions are
random, independent draws from the same probability distribution, although there are also
methods that consider the data structure, generally in terms of maintaining outcome class
proportions between the training and testing data sets [49, 59, 132]. In this study, we propose a
new cross validation method, proportional instance cross validation (PICV), that preserves the
relative distribution of an independent variable (in our example application, SNP-SNP interaction
genotypes) when dividing the overall data set into train and test partitions. We demonstrate
significantly improved sensitivity and positive predictive value across all tested scenarios with
application of PICV relative to a traditional cross validation implementation. We additionally apply
PICV to primary open-angle glaucoma GWAS data to investigate an interaction previously
reported to be significant in two independent data sets. Although this interaction is not observed
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to be significant in our analysis, PICV produced more consistent estimates than a traditional cross
validation implementation. This approach is not only appropriate for epistasis data but may be
readily applied to comparable imbalanced variable problems.

Methods
Data set generation
All data sets were generated using GAMETES, a tool that produces epistatic models between
SNPs and creates data sets based off these models [131]. Penetrance functions were generated
for SNP-SNP interaction scenarios for all 15 combinations of minor allele frequencies (MAFs) of
{0.5, 0.4, 0.3, 0.2, and 0.1}, with SNP heritability kept constant at 0.005 and population
prevalences of 0.5, 0.1, and 0.02 (Table 1, Supplemental tables 1-2). Although a prevalence of
0.5 may seem high for a given disease, numerous risk factors for chronic and complex diseases
in the United States population that may be phenotypes of interest are as or more prevalent,
including being overweight or obese, lack of physical activity, excessive sodium consumption,
lack of fruit and vegetable consumption, etc [30]. The simulated data with prevalence of 0.1 is
intended to reflect the US prevalence of common complex diseases such as diabetes or
cardiovascular disease [100]. The simulated data sets of 0.02 prevalence approximately reflect
the US prevalence of primary open-angle glaucoma, which is investigated in the real data
application [51]. Balanced case-control ratio data sets of size 2,000 and 10,000 were generated
for the 0.5 prevalence scenario and of size 10,000 for the 0.1 and 0.02 prevalence scenarios.
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SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

Scenario 1
0.1
0.1
0.493
0.531
0.522
0.526
0.387
0.410
0.611
0.008
0.358

Scenario 2
0.2
0.1
0.507
0.480
0.556
0.471
0.590
0.249
0.485
0.532
0.482

Scenario 3
0.2
0.2
0.514
0.481
0.425
0.467
0.544
0.674
0.539
0.447
0.304

Scenario 4
0.3
0.1
0.513
0.494
0.456
0.438
0.530
0.696
0.520
0.475
0.506

Scenario 5
0.3
0.2
0.488
0.525
0.450
0.527
0.455
0.562
0.478
0.458
0.814

Scenario 6
0.3
0.3
0.481
0.533
0.446
0.525
0.468
0.513
0.483
0.470
0.734

Scenario 7
0.4
0.1
0.484
0.501
0.535
0.570
0.494
0.359
0.545
0.551
0.245

Scenario 8
0.4
0.2
0.490
0.523
0.455
0.512
0.468
0.568
0.565
0.395
0.668

Scenario 9
0.4
0.3
0.502
0.523
0.425
0.499
0.472
0.588
0.495
0.503
0.501

Scenario 10
0.4
0.4
0.476
0.535
0.449
0.506
0.473
0.568
0.536
0.503
0.410

Scenario 11
0.5
0.1
0.306
0.333
0.341
0.428
0.314
0.256
0.322
0.198
0.595

Scenario 12
0.5
0.2
0.476
0.521
0.482
0.521
0.472
0.536
0.715
0.392
0.502

Scenario 13
0.5
0.3
0.500
0.520
0.459
0.477
0.480
0.563
0.608
0.482
0.429

Scenario 14
0.5
0.4
0.422
0.515
0.547
0.548
0.491
0.470
0.531
0.492
0.485

Scenario 15
0.5
0.5
0.440
0.560
0.440
0.522
0.484
0.509
0.515
0.472
0.542

Table 6. Data set simulation parameters. Minor allele frequencies and penetrance tables used to
generate balanced case-control ratio data sets of size 2,000 and 10,000. Heritability = 0.005 and
prevalence = 0.5 constant across all simulations.

Implementation and evaluation of traditional cross validation

For each of the 15 scenarios for each investigated prevalence and sample size
combination, we perform 1000 replicates of a standard cross validation procedure in which
two-thirds of observations are randomly allocated to be used for training and the remaining
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third is used for testing. The training data is then used to fit the following logistic regression
models with and without the SNP-SNP interaction:

(1)

(2)

Where P(case) is a binary indicator of case-control status, SNP1 and SNP2 are categorical
variables in which 0 corresponds to the homozygous dominant genotype, 1 to the heterozygous,
and 2 to the homozygous recessive, and SNP1*SNP2 corresponds to the Cartesian product of
the two {00, 01, 02, 10, 11, 12, 20, 21, 22}.

These models fit to the training data are then used to predict case-control status for the
held-out testing data, using a cutoff of 0.5 for case versus control prediction assignment
from the fitted values. These predictions are then used to calculate the sensitivity,
specificity, positive predictive value, and negative predictive value for the testing data.

Implementation and evaluation of proportional instance cross validation (PICV)

For the proportional instance cross validation procedure, rather than randomly allocating
each observation to be included in the training or testing set, observations are allocated in a
genotype-specific fashion (Figure 1). Two-thirds of the observations of each SNP-SNP
genotype are randomly allocated to be used for training and the remaining third is used for
testing. Therefore the same total proportion of individuals used for training versus testing is
maintained as in the traditional cross validation procedure, and additionally, the relative
proportions of each genotype are preserved between the overall data set and the training
and testing partitions. Model fitting with the training data, testing data predictions, and
performance measure calculations are conducted as for the traditional cross validation.
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Figure 1. Comparing traditional cross validation and proportional instance cross validation
(PICV). A) The overall distribution of 9 SNP-SNP interaction genotypes in a population of
individuals. B) Traditional cross validation in which 2/3 of observations are randomly
allocated to the training set and the remaining 1/3 are allocated to the testing set can result
in draws with imbalanced genotype proportions. C) PICV randomly allocates 2/3 of
observations of each genotype to the training set and the remaining 1/3 to the testing set,
ensuring that the relative proportions of genotypes are maintained.

Comparison of traditional cross validation and proportional instance cross validation
(PICV)

For both traditional cross validation and PICV, we calculate the absolute value of the
difference between training and testing for each of four performance measures (sensitivity,
specificity, positive predictive value, and negative predictive value) over 1,000 trials for each
of the 15 scenarios. We calculate p-values for the two-sample Kolmogorov-Smirnov test
with the null hypothesis that there is no difference between the traditional cross validation
implementation and PICV distributions of the difference between training and testing for
each performance measure, with the one-sided alternative that the PICV distribution is
smaller, with a significance threshold of α = 0.05.

Results
Implementing PICV for our simulated epistasis examples (that is, performing cross validation data
set splitting such that observations are allocated to maintain the same relative proportions of each
SNP-SNP genotype in the training and testing sets as in the data set overall) significantly
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improved the consistency between training and testing sensitivities and positive predictive values.
Figure 2 illustrates comparisons of training/testing consistencies for PICV versus a traditional
cross validation procedure in which observations are allocated to the training and testing sets
without regard to genotype (see Supplemental Figures 1-60 for all minor allele frequency,
prevalence, and cohort size combinations). P-values listed are for the two-sample KolmogorovSmirnov test of the distributions of the absolute values of the differences between the training and
testing performance measure (e.g. sensitivity) over 1,000 trials per scenario for these two cross
validation approaches, with a one-sided alternative hypothesis that the split-by-genotype
distribution is smaller. Table 2 summarizes these performance measures across all 15 SNP-SNP
genotype MAF combination scenarios for the 0.5 prevalence simulations of size 2,000 (see
Supplemental Table 3 for prevalence = 0.5 and n = 10,000, Supplemental Table 4 for prevalence
= 0.1, Supplemental Table 5 for prevalence = 0.02). Sensitivity and positive predictive value were
significantly more consistent between test and train for PICV than for traditional cross validation
across all 15 scenarios tested for both n=2,000 and n=10,000. Although the specificity and
negative predictive value comparisons mostly did not meet statistical significance, smaller
medians and maximum values for the differences in these performance measures between
training and testing were observed for the PICV approach for the majority of scenarios (Table 3).
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Figure 2. Consistency of training and testing performance measures for models with and without
the interaction term, comparing a traditional cross validation procedure to PICV. Experimental
scenario in which both SNPs have a MAF of 0.5, prevalence = 0.5, n=2,000.
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Table 2. Summary of performance measures across minor allele frequency combinations,
prevalence = 0.5, n = 2,000.
Measure,
Model
Scenario
SNP1 MAF: 0.1
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.1
SNP1 MAF: 0.3
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.1
SNP1 MAF: 0.4
SNP2 MAF: 0.2
SNP1 MAF: 0.4
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.1
SNP1 MAF: 0.5
SNP2 MAF: 0.2
SNP1 MAF: 0.5
SNP2 MAF: 0.3
SNP1 MAF: 0.5
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.5

Sens,
without
int

Sens,
with int

Spec,
without
int

Spec,
with int

PPV,
without
int

PPV,
with int

NPV,
without
int

NPV,
with
int

3.06e-17

9.89e-08

N.S.

N.S.

1.90e-18

7.67e-08

N.S.

N.S.

7.04e-20

4.54e-05

3.88e-02

N.S.

3.68e-11

5.56e-06

4.35e-02

1.89e-02

1.69e-10

1.69e-10

N.S.

6.87e-03

4.06e-09

4.06e-09

N.S.

N.S.

1.59e-08

2.47e-05

4.35e-02

N.S.

9.27e-09

2.47e-05

3.46e-02

N.S.

6.14e-04

5.02e-11

N.S.

N.S.

3.07e-16

1.22e-14

N.S.

N.S.

5.16e-04

4.33e-04

N.S.

N.S.

1.75e-04

1.75e-04

N.S.

N.S.

9.94e-05

7.67e-08

N.S.

N.S.

3.52e-08

5.53e-10

N.S.

N.S.

6.65e-17

1.45e-04

N.S.

N.S.

5.36e-09

2.42e-02

N.S.

N.S.

2.71e-08

4.54e-05

N.S.

N.S.

8.97e-07

4.46e-06

N.S.

N.S.

1.63e-05

1.41e-03

N.S.

N.S.

2.66e-03

8.62e-04

N.S.

N.S.

8.97e-07

7.06e-09

N.S.

N.S.

2.27e-06

1.27e-07

4.85e-03

N.S.

9.42e-18

6.75e-05

1.28e-02

N.S.

4.00e-12

8.60e-06

N.S.

N.S.

4.38e-07

2.47e-05

N.S.

N.S.

7.67e-08

4.12e-10

N.S.

1.46e-02

2.69e-07

5.54e-05

N.S.

N.S.

7.06e-09

8.62e-04

N.S.

N.S.

1.27e-07

6.92e-06

N.S.

1.54e-02

2.89e-12

9.27e-09

N.S.

N.S.

Table 3. Number of scenarios for which PICV yielded smaller median, maximum differences
between training and testing, n = 10,000

Measure, Model
Specificity, without
interaction
Specificity, with
interaction
NPV, without
interaction
NPV, with
interaction

PICV median less than
traditional CV median (out of 15)
Prevalence
0.02
0.1
0.5

PICV maximum less than
traditional CV maximum (out of 15)
Prevalence
0.02
0.1
0.5

15

15

12

15

15

15

15

15

15

15

15

15

14

9

9

11

8

8

8

9

10

8

9

9
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Primary open-angle glaucoma interaction analysis
Prior interaction analyses of primary open-angle glaucoma identified several pairs of replicating
interactions using the eMERGE and NEIGHBOR data [136]. We attempted to replicate the most
significant interaction (between ALX4 and RBFOX1) in the GLAUGEN data set (dbGaP Study
Accession: phs000308.v1.p1, available at https://www.ncbi.nlm.nih.gov/gap), which is
harmonized with NEIGHBOR. The GLAUGEN model is adjusted for age, sex, site, and the first 6
principal components to reflect the eMERGE and NEIGHBOR models (the eMERGE and
NEIGHBOR models additionally adjusted for platform, but all GLAUGEN samples were assessed
on the same platform). Our analysis did not find a significant interaction between the two variants
(Table 4). However, application of PICV to this data did yield training and testing p-values (0.376
and 0.323, respectively) more consistent with the overall LRT p-value (0.327) than a traditional
cross validation procedure (0.442 and 0.470, respectively).

Table 4. Comparison of interaction significance across data sets
Data set
eMERGE
NEIGHBOR
GLAUGEN

ALX4 variant
rs10838251
rs7126447
rs7126447

RBFOX1 variant
rs653127
rs11077011
rs11077011

LRT p-value
7.29E-06
1.62E-06
0.327

Discussion
Implementing a cross validation splitting procedure that maintains the relative proportions of each
SNP-SNP genotype when dividing the overall data set significantly improved the sensitivity and
positive predictive value consistencies between the training and testing partitions in each of the
experimental scenarios tested. Although specificity and negative predictive value improvement
did not meet statistical significance in most cases, application of the PICV approach did yield
smaller median and maximum absolute differences between training and testing in the majority of
scenarios. The interaction analysis did not replicate the prior finding between ALX4 and
RBFOX1, however PICV still produced more consistent estimates than a traditional cross
validation procedure for this data. Verma et al note that RBFOX1 has been previously shown to
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be associated with myopia, and that eMERGE primary open-angle glaucoma cases had not been
screened for myopia; GLAUGEN excluded individuals with more than 8 diopters of myopia. This
inconsistent finding highlights the importance of considering epidemiological confounders and comorbidities of complex phenotypes in genetic analyses.
Class imbalance is a well-recognized issue in machine learning analyses, particularly for the
analysis of high-dimensional data sets as in genomics and other biomedical applications [80]. If
the main objective of a machine learning analysis is maximizing accuracy, and the minority class
is very small, simply predicting the majority class for each observation may yield high overall
accuracy, as in the spam filtering problem [56]. Clearly, adoption of a balanced accuracy measure
or a cost-sensitivity analysis that weighs the relative importance of avoiding false positives versus
false negatives is critical for such problems, and numerous methods have been developed to
address this issue including novel fitness functions, sampling-based approaches, and ensemble
methods, including for epistasis modeling [52, 83, 86, 134]. The present study, though
thematically similar to the class imbalance problem, instead addresses imbalance in observations
of classes of an independent variable, e.g. the SNP-SNP interaction genotype. This is also
adjacent to the covariate and data set shift problems, in which the training and testing
distributions differ (for example due to model training using clean data from consistent laboratory
conditions to produce models that then fail to hold for experimentally gathered data with
unanticipated environmental differences), but for internal cross validation [1, 123, 126]. Solutions
to problems of both of these genres include re-weighting and –sampling techniques, whereas the
present study circumvents the need for either via splitting the data to ensure balanced proportions
by genotype between training and testing sets. The example application of imbalanced SNP-SNP
genotypes considers a categorical variable, but the underlying idea of preserving the distribution
of instances between training and testing with regard to an independent variable could be
extended to continuous variables or combinations of variables via binning, propensity scores, etc.
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Conclusions
Although the contribution of epistatic interactions may help explain the “missing heritability” of
complex disease, statistical detection of epistasis remains challenging and can require
adjustment of general machine learning protocols. With decreasing minor allele frequencies, the
number of observations for rare SNP-SNP interaction genotypes becomes quite small in a GWAS
of typical size, and a standard cross validation procedure may result in training/testing data set
splits that poorly represent the data as a whole. This diminishes the ability to identify interactions
of potential interest for experimental follow-up, and underscores the need to perform interaction
analyses in an interaction-specific framework. A potentially overlooked element of performing
reproducible analyses includes the imperative to develop and modify methods considering how
intrinsic characteristics of the data and its structure may contribute to statistical failure to replicate
despite biological (or other scientific) validity. Genomics and the biomedical sciences in general
benefit from their increasingly multidisciplinary nature by incorporating methodology and theory
from adjacent computational fields, but thoughtful contextualization of the data in view of the
underlying biology is necessary to reap the potential benefits of applied machine learning
methods and to successfully reproduce them.
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IDENTIFICATION OF EPISTATIC INTERACTIONS BETWEEN THE HUMAN RNA
DEMETHYLASES FTO AND ALKBH5 WITH GENE SET ENRICHMENT ANALYSIS
INFORMED BY DIFFERENTIAL METHYLATION
Introduction
The Genetic Analysis Workshop (GAW) is a forum for investigators to develop and critique new
analytical methods for complex traits on a shared data set. The GAW20 data provide simulated
replications based on the Genetics of Lipid-lowering Drugs and Diet Network (GOLDN) clinical
trial, had participants been subject to treatment with a fictitious drug with a pharmaco-epigenetic
effect on triglyceride response [66]. These data present a unique analysis opportunity as all
phenotypes, subject covariates, genotypes, pre-treatment methylation levels, etc. are real data
from the trial, but are accompanied by simulated post-treatment methylation and triglyceride
levels. GAW participants choose to analyze the data with or without knowing the simulation
methods; the simulated data analysis was performed prior to attending GAW, without knowledge
of the simulation methods. Analysis of the real data was performed following GAW attendance, as
it was revealed that the data simulation methods did not consider interactions, and therefore
analysis of interactions in the simulated data was not appropriate.
Despite evidence for multi-locus underpinnings of phenotype-genotype association, the multipletesting burden associated with fitting interaction models is stringent due to the high dimensionality
of genomic data [90]. Strategies for better detecting these interactions can aim to avoid
exhaustively testing each potential interaction via data reduction methods, integrating expert
knowledge, and/or consolidating multiple sources of evidence to narrow the search space [26, 97,
113].
In this study, we hypothesize that CpG sites that are differentially methylated with respect to
treatment are associated with the pharmaco-epigenetic mechanism of the fictitious drug.
Considering the evidence for multi-locus models of complex disease etiology, we hypothesize
that the drug response is better evaluated by gene set enrichment analyses than single locus
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models. By integrating results from Gene Ontology (GO), drug-disease association, and
microRNA (miRNA) target analyses we find evidence implicating the relevance of adenosine and
miRNAs with known epigenetic regulation and roles in lipid metabolism. From this, we infer the
potential importance of the N6-methyladenosine modification in the pharmaco-epigenetic
response on triglycerides, and consider how miRNA adenosine methylation rather than CpG
methylation may impact the phenotype. Lacking direct data for miRNA adenosine methylation, we
perform a targeted epistasis search between loci on the two RNA demethylases FTO and
ALKBH5, and find evidence for statistical epistasis between one variant within each respective
gene. Repeating the analysis with the real data revealed four significant interactions between
variants across these genes. Overall, we present an example workflow (Figure 1) in which
integration of multiple sources of information can help uncover biological meaning in the absence
of significant main effects.
CpG site filtering

Paired t-tests for pre- and posttreatment methylation levels

α = 0.05
463,995 hypotheses
Bonferroni cutoff 1.08 x 10-7
212,018 pass

Modeling relationship
between phenotype and
CpG site methylation

Linear models:
log ratio of post-treatment to pretreatment TG level ~ log ratio of posttreatment to pre-treatment methylation

α = 0.05
212,018 hypotheses
Bonferroni cutoff 2.36 x 10-6
NONE pass
4433 gene list constructed from all CpG
sites with p-values ≤ 0.05

Gene set enrichment
analyses

WebGestalt enrichment analyses

Gene ontology
Drug association
MicroRNA targets
Top drug: Adenosine (8 x 10-21)
Top miRNA: miR-124a (1.70 x 10-42)

Targeted epistasis search

Likelihood ratio test comparing models
with and without the interaction
Only interactions of SNPs between the
two genes FTO and ALKBH5, not within

α = 0.05
340 hypotheses (simulated)
255 hypotheses (real)
Bonferroni cutoff 0.00015 (simulated)
Bonferroni cutoff 0.000196 (real)
One significant interaction (simulated)
Four significant interactions (real)

Figure 1. Workflow overview and results summary
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Data set and methods
Data set
The GOLDN data and companion simulations for GAW20 are previously described [66]. Relevant
to this analysis, subject data includes fasting lipid profiles prior to and post-treatment, methylation
at > 450,000 CpG sites prior to and post-treatment, GWAS of > 700,000 autosomal SNPs, and
covariates including age, center, metabolic syndrome-related traits, and smoking status. This
analysis is of the pre-defined single representative replicate (n=680) of the post-treatment
methylation and triglyceride levels.

Phenotype definition
We define the phenotype of interest as the log ratio of the average post-treatment triglyceride
level to the average pre-treatment triglyceride level. Due to the high correlations between
triglyceride levels at pre-treatment time points 1 and 2 and post-treatment time points 3 and 4
(0.90 and 0.91, respectively), and presence of a value for at least one of time point 1 or 2 and 3
or 4 for each individual, we singly impute missing values via linear regression.

CpG site filtering
Significantly differentially methylated CpG sites are identified via paired t-tests for pre- and posttreatment methylation levels (α = 0.05 for 463,995 hypotheses yields Bonferroni cutoff of 1.08 x
10-7).

Modeling the relationship between phenotype and CpG site methylation
Linear models are fit to test the relationships between the phenotype and methylation status of
the significant CpG sites identified above, characterized as a single predictor: the log ratio of
post-treatment to pre-treatment methylation (α = 0.05 for 212,018 hypotheses yields Bonferroni
cutoff of 2.36 x 10-6).
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Gene set enrichment analyses
All CpG sites that pass the initial t-test filter and have a p-value ≤ 0.05 for the phenotype ~
methylation predictor model are used to curate a list of corresponding genes with evidence for
both differential methylation and association with the phenotype. This gene list is used for Gene
Ontology, drug association, and microRNA target enrichment analyses using the WEB-based
GEne SeT AnaLysis Toolkit (WebGestalt, http://www.webgestalt.org/) [144].

Targeted epistasis search
We investigate potential epistasis between the two RNA demethylases FTO and ALKBH5 by
calculating p-values for the likelihood ratio tests comparing the linear models containing each
FTO SNP – ALKBH5 SNP pair, with and without their interaction term (α = 0.05 for 340
hypotheses yields Bonferroni cutoff of 0.00015 for the simulated data, 255 hypotheses yields a
cutoff of 0.000196 for the real data).

Results
CpG site filtering
We tested 463,995 CpG sites for differential methylation prior to versus post-treatment. 212,018
CpG sites passed the Bonferroni threshold of 1.08 x 10-7.

Modeling the relationship between phenotype and CpG site methylation
None of the 212,018 CpG sites that are significantly differentially methylated reached genomewide significance for association with the phenotype (Figure 2).
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Figure 2. Manhattan plot of triglyceride phenotype ~ CpG site methylation log ratio

Gene set enrichment analyses
Our gene set is constructed from all CpG sites with p-values ≤ 0.05 for the models above for
which corresponding gene annotations are available (5413 of the 212,018 differentially
methylated sites). Some CpGs have more than one corresponding gene listed, and many genes
have multiple CpGs, for a total gene list length of 4443. The top result from the drug association
analysis is adenosine (number of reference genes in the category = 477, number of genes in the
gene set and also in the category = 126, expected number in the category = 49.14, ratio of
enrichment = 2.56, raw p value from hypergeometric test = 1.31 x 10-23, p value adjusted by
multiple test adjustment = 8 x 10-21). The top result from the miRNA target analysis is miR-124a
(number of reference genes in the category = 542, number of genes in the gene set and also in
the category = 175, expected number in the category = 55.84, ratio of enrichment = 3.13, raw p

45

value from hypergeometric test = 7.82 x 10-45, p value adjusted by multiple test adjustment = 1.70
x 10-42).

Targeted epistasis search
The GAW20 GWAS data with the simulated phenotype include complete observations for 68
SNPs on FTO and 5 SNPs on ALKBH5 for the 680 subjects. We only test for epistatic interactions
between SNPs across the two genes (and do not test for interactions between SNPs on the same
gene), for a total of 340 tested interactions and therefore a Bonferroni threshold of 0.00015. One
pair of SNPs, rs2192872 from FTO and rs8068517 from ALKBH5 have a significant p-value for
the likelihood ratio test comparing the models with and without the interaction (p = 2.01 x 10-5).

The analysis of the real phenotype and GWAS data was performed in the same manner for 778
subjects for 51 SNPs on FTO and 5 SNPs on ALKBH5 (Bonferroni threshold of 0.000196). Four
pairs of SNPs have significant p-values for the likelihood ratio test comparing the models with and
without the interaction (Table 1). Figure 3 visually summarizes the distribution of phenotype by
genotype for the two SNPs involved in the most significant identified interaction.

Table 1. Summary of significant interactions. Variant annotations are from Ensembl [142]. Base
model covariate selection is based on significance at the 0.05 level and includes average pretreatment triglyceride level, age, center, current smoker status, and sex.
SNP
rs1362571

Alleles
G/T

MAF
0.34 (G)

Location
16:53877858

Gene
FTO

Consequence Type
Intron variant

LRT p-value
2.76 x 10-6

rs11655588

A/G

0.18 (G)

17:18204137

ALKBH5

Intron variant

rs10521304

T/C

0.41 (C)

16:53874745

FTO

Intron variant

rs11655588

A/G

0.18 (G)

17:18204137

ALKBH5

Intron variant

rs1421090

A/G

0.29 (G)

16:53816258

FTO

Intron variant

rs8071834

T/C

0.45 (C)

17:18196677

ALKBH5

Intron variant

rs17820875

A/G

0.12 (G)

16:53892878

FTO

Intron variant

rs8068517

G/A

0.24 (G)

17:18192664

ALKBH5

Intron variant

8.80 x 10-6

0.000158

0.000177
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Figure 3. Phenotype distributions by genotype. A. Phenotype distributions for individuals with 0,
1, or 2 copies of the minor allele for rs1362571. B. Phenotype distributions for individuals with 0,
1, or 2 copies of the minor allele for rs11655588 amongst those with 0 copies of the minor allele
for rs1362571 [left]; 1 copy [center]; 2 copies [right]. C. Phenotype distributions for individuals with
0, 1, or 2 copies of the minor allele for rs11655588. D. Phenotype distributions for individuals with
0, 1, or 2 copies of the minor allele for rs1362571 amongst those with 0 copies of the minor allele
for rs11655588 [left]; 1 copy [center]; 2 copies [right].
The significant pair of SNPs identified from the simulated analysis did not reach significance in
the analysis of the real data, although one of the SNPs (rs8068517) was a member of one of the
significant interactions. Upon interrogating the phenotype distributions by genotype for the
simulated data (Supplemental Figure 1), the real data (Supplemental Figure 2), and those
individuals from the real data who were not included in the simulated data (Supplemental Figure
3), this appears to be driven by the 98 individuals who differ between the simulated and real data
analyses. Although the differences in phenotype values by genotype between the real and
simulated data may not appear extreme, the inclusion or exclusion of a small number of
individuals may in fact significantly perturb the observed interaction. For example, there are 4
total individuals with 2 copies of the minor allele for rs2192872 and 0 copy of the minor allele for
rs8068517 in the real data with a mean phenotype value of 0.900 (Supplemental Table 1). The
simulated data includes only 2 of these individuals, for a mean phenotype value of 0.874, which
makes this interaction appear much more protective compared to other interaction genotypes
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(particularly when considering the phenotype is defined as the log ratio of the average posttreatment triglyceride level to the average pre-treatment triglyceride level).

Discussion
Our gene set enrichment analyses were motivated by the goal of making inferences about the
mechanism of action of the fictitious drug, assuming that differential methylation could reveal a
set of genes associated with a drug that is functionally similar to the fictitious one in question.
Upon attending GAW, it became apparent that interaction analysis of the simulated data was not
appropriate given the nature of the simulation, and the interaction identified can therefore be
considered a false positive. However, re-implementing the same analytic pipeline using the real
data produced largely comparable results and identified four pairs of loci between FTO and
ALKBH5 with significant interactions. The joint evidence implicating adenosine as the top result
from the drug association gene set enrichment analysis and numerous miRNAs involved in
metabolic traits from the miRNA target analysis, taken with the assumption that the drug has
some unknown epigenetic mechanism, lead us to consider that mRNA or miRNA adenosine
methylation, rather than CpG methylation, may be associated with drug response. MiRNAs in
general are known important regulators of lipid metabolism [31, 50, 88]. The top miRNA hit, miR124a, has evidence for both its role in metabolic traits [7, 37, 73, 122], and for its epigenetic
regulation in the context of risk of diverse diseases [2, 15, 20, 35, 41]. N6-Methyladenosine (m6A)
is a reversible, dynamic post-transcriptional modification that is regulated by miRNAs, and its
demethylation has been shown to regulate adipogenesis [18, 34, 82]. Recent work has
demonstrated that RNA conformational changes induced by m6A determine substrate specificity
for the two RNA demethylases, FTO and ALKBH5 [145]. If miRNA adenosine methylation rather
than CpG methylation affects the phenotype, although the available data lacks observations on
miRNA adenosine methylation, interactions between the two genes that demethylate miRNAs
may be biologically relevant and can be assessed with the GOLDN SNP data. Given the
evidence for physical interactions between RNA with the m6A mark and these demethylases, we
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were motivated to check for epistasis between SNPs on these genes. Although we did find four
pairs of loci with statistically significant interactions, the small sample size means that some SNPSNP genotypes have few observations, warranting investigation of this interaction in a larger
study and further molecular clarification of the distinct and mutual roles of FTO and ALKBH5.
Rather than attempting to explain complex phenotypes solely in terms of single locus main
effects, we posit that interaction models better represent the underlying regulatory nature of the
genome, and that the joint effect of perturbations to multiple interacting partners can help better
explain complex phenotypes. This analysis of epistatic interactions between loci on two genes
serves as an illustrative example of how interactions can be significant in the absence of
significant main effects, and highlights the need for analyses that integrate multiple sources of
data to narrow the search space for plausible interactions.
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CONCLUSIONS
Summary of the present work
The present work arises from the need to integrate and analyze large amounts of genomic data
with a focus on challenges to the ability to detect and replicate epistatic interactions. Epistatis, or
deviations from additivity in the interaction of genotypes to produce the resultant phenotype, may
help explain the “missing heritability” of complex disease, but can be difficult to detect statistically
due to the multiple testing burden associated with naively testing all pairwise combinations of loci.
Furthermore, the potential for significant interactions in the complete absence of single locus
main effects of the interacting partners and vice versa complicates prioritization of loci to test
based on filtering via presence of significant main effects. Narrowing the search space to alleviate
the multiple testing burden requires either the development of methods that consider qualities
intrinsic to the data that may affect the power to potentially detect an interaction (such as low
minor allele frequencies of the SNPs being investigated), or integration with supplemental
sources of information that can provide additional context to be used for filtering or other feature
selection. Beyond the difficulty associated with detecting an interaction, replication of an
interaction may be hindered by population-level differences in allele frequency, heritability,
prevalence, or other demographic, clinical, or environmental variables. Furthermore, differences
in the computational pipeline used to analyze this data (including the ordering of workflow steps,
quality control cutoffs, versions of dependent software, etc.) may determine whether an
interaction is tested in the first place or thereafter ascertained to be significant. This necessitates
the consideration of how standard statistical analyses, quality control and data cleaning
procedures, or parameter tuning choices in machine learning analyses can be modified to
improve the ability to detect and replicate epistasis.

I begin with a review on improving the reproducibility of machine learning analyses of genomic
data, in which I discuss the distinctions between reproducibility and replicability, highlight potential
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barriers to performing analyses of genomic data, emphasize and the difficulty of detecting and
replicating interactions, and consider how choices at each stage of a machine learning analysis
may impact its results. This review highlights impediments to genomic big data analyses and
suggests topics of open interest to contextualize the present work. The following two chapters
describe methods for improving the reproducibility of interaction analyses of genomic data:
implementing a resampling technique to recapitulate the power to detect interactions across
populations with differences in minor allele frequencies, and implementing a cross validation
technique that preserves relative genotype proportions to allow for improved detection of
interactions for internal feature selection. These methods address barriers to replication of
epistatic interactions between populations and reproducibility of interaction detection within a data
set, respectively. The final chapter presents an example of an analysis that leverages a
secondary data source with no significant association between methylation and the phenotype at
any site to narrow the search space for further gene set enrichment and interaction analyses to
find statistically significant interactions between the two RNA demethylases FTO and ALKBH5.
This serves to emphasize that even “negative” data may be useful for contextualizing or
supplementing other data sources, and by extension underscores the utility of GWAS data as one
of many informative data sources that can be consolidated to produce a comprehensive,
integrated personalized health risk assessment.

Overall, this work highlights and addresses some of the concerns emerging from the rapid
coalescence of genomics and data science, and how experimental and analytical design choices
in both domains and their fusion can greatly impact results. Understanding the downstream
consequences of these choices and how they may feed in to each other demands in-depth
interrogation of many small perturbations to the entire experimental process from the wet lab or
clinic to the cloud. The future of high-quality, reproducible biomedical science will increasingly
require the engagement of experts from diverse domains, underscoring the importance of
harmonizing technical or analytical advances from other fields to suit the unique structure and
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biases of new data sources. The combination of technological and computational improvements
that allow for the unprecedented rate of biomedical data accumulation, and the increasing
emphasis on the importance of reproducible, interdisciplinary, and translational research can
converge to enable an era of unprecedented scientific productivity and advancement through the
cooperation of many agents. The following passages describe potential extensions of the present
work and considerations for future research that arise from the present work.

Future directions
A logical extension of the present work is interrogating how the proposed resampling, cross
validation, and data integration techniques may differentially influence findings across machine
learning methods and how they may need modification to appropriately suit the particularities of
each method. This work has investigated how factors such as minor allele frequency, prevalence,
heritability, sample size, etc. impact results in the context of logistic regression models and uses
the likelihood ratio test of the models with and without the interaction to quantify the significance
of an interaction, as per standard analyses of GWAS data. However, we should consider other
methods for detecting interactions and quantifying evidence of significance, how consistent these
methods are with each other, and whether some are particularly suited for certain classes of
problems. This may become increasingly important especially as analyses of GWAS data include
integration or supplementation with external data sources that heighten the computational,
storage-related, and interpretive demands. The choice of algorithm and its relevant parameters
or hyperparameters, the ordering of steps in an analytic workflow, and the potential propagation
of errors associated with integrating multiple methods and data types and sources must all be
investigated to determine their relative contributions to failure to replicate across a range of
population parameters.
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Relatedly, the emphasis on statistical significance and p-values alone does a disservice to
improving replication of both main effects and interactions. As data becomes sufficiently large,
researchers are essentially guaranteed to find significant results, but the practical interpretation of
these may be lacking. Re-analyzing existing GWAS data considering consistency in the direction
and magnitude of effects for findings that fail to reach statistical significance and supplementing
analyses with orthogonal data sources may provide additional informative clues regarding the
underlying genetic architecture. A new GWAS analysis paradigm may be the automated metaanalysis of all new studies in the context of relevant evidence from prior studies. Such a system
could also be used to prioritize which variants would be most informative to focus on in
subsequent work, for example variants of large effect size that fail to reach statistical significance
or variants at very different frequencies between populations. However, the results of metaanalyses may unfortunately obscure true relationships due to differences in bias between data
sources, inconsistent phenotyping, unmeasured epidemiological confounding, or opposite
directions of effect between populations. This highlights the adjacent importance of performing
smaller, very well-controlled and precisely-defined studies across multiple homogeneous
populations to better define and understand common versus subgroup-specific factors in the
genetic architecture underlying traits to enable identification of barriers to replication. For
example, it may be necessary to perform separate analyses of men and women in order to
identify determinants of risk that differ by sex such as variants or interactions with variants on the
X or Y. Sex-specific analysis may be especially worth consideration in light of non-genomic
differences in exposures that may modify risk, such as behavioral or hormonal factors. Simulation
studies that aim to characterize the ability to detect and replicate interactions across differentially
confounded studies with the same true causal interaction may provide insight in interpreting real
data with unknown sources of confounding.

The interactions explored in the application of PICV to primary open-angle glaucoma data and in
the GAW analysis provide additional opportunities for follow-up in confounder analyses and data
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integration methods. Both of these interaction analyses may be improved via integration of
additional sources of data such as tissue-specific gene expression data. The potential
confounding by myopia identified in the PICV analysis suggests a need to better integrate
genomic and traditional epidemiologic data and to design studies and develop analytic methods
that can better facilitate exploration of gene-by-environmental and higher order combinations of
genetic and environmental effects, perhaps with combined genomic and environmental matching
and weighting techniques. The PICV analysis may for example be supplemented by data from
genomic analyses of myopia, particularly with known glaucoma status and measured diopters of
correction.

Towards greater reproducibility in the biomedical sciences
Although numerous fields grapple with concerns raised by the reproducibility crisis, this anxiety
can be embraced as an opportunity to critique and radically reconsider how current scientific
traditions and practices contribute to a culture of irreproducibility and the measures that can be
taken towards creating structures and systems to enable more reproducible science. Improving
reproducibility in genomics and the biomedical sciences more broadly will, besides technical
advances in both the experimental and analytical branches, require improved integration of data
collection and analysis, particularly in linking and jointly analyzing many heterogeneous data
sources. Streamlining experimental workflows to autonomously and consistently collect and clean
data in the format appropriate for analysis can reduce the potential for accidental input errors.
Expanding this paradigm to facilitate the linking or integration of multiple data types in a
standardized way can further promote reproducible analysis. Studies may reasonably need to
synthesize data of diverse types and formats in order to consider patient demographics and
personal history, family history, doctor’s notes, lab results, personal genome testing results,
wearable device tracking output, etc. Analyzing this data in a reproducible framework that
considers their intrinsic biases, levels of missingness, and relationships to each other suggests
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the need for a standardized personalized medicine hierarchy or ontology. Formalizing the
hierarchical structures of the relationships between concepts could facilitate the exploration of risk
attributable to perturbing exposures individually and in the context of confounders or effect
measure modifiers. Such a structure could also improve the ability to compare findings between
populations with different exposures and genetic architectures and provide a framework for
modeling these differences or using them for weighting predictions.

Efforts to synthesize this data will likely require the expertise of individuals from numerous fields
including the clinical sciences, basic sciences, computer sciences, informatics, statistics, etc. as
the depth and breadth of necessary knowledge and skills is beyond an individual traditional
academic domain. In addition to enhancing interdisciplinary exposures in the classroom or
providing more workshop opportunities to develop working knowledge of important concepts in
adjacent fields, the increasing need for scientists of diverse backgrounds to work together can be
facilitated by creating more interdisciplinary programs to train scientists who can straddle these
fields and serve as liaisons. Current training programs may also offer greater opportunities for
trainees to interact between departments, perhaps via course offerings that may benefit diverse
types of trainees (such as introductory programming and statistics courses) or research lecture
series to promote current interdisciplinary expertise needs to solicit desired collaborators from
other departments. This effort could be expanded to be independent of home institution via a
research matchmaking web service, which would further foster relationships between scientists of
varying experience and expertise around the world by connecting potential collaborators,
mentors, or trainees. Seeking multiple mentors of differing expertise can provide a student with a
well-rounded training experience that enhances interdisciplinary skills, while supporting trainees
with a diverse range of research interests can help more established scientists stay connected to
current interdisciplinary advances. Promoting overlap in domain expertise, as opposed to more
rigidly defining specialization, is critical to the advancement of reproducibility in interdisciplinary
academia. Scientists from more diverse training programs and with more diverse networks of
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collaborators can help mitigate the potential for misunderstandings that may arise from fieldspecific differences in vocabulary, conceptual false friends, etc. They may also be particularly
poised to recognize how standards, practices, or tools from one traditional field may be
superimposed upon or modified to suit analogous problems in another. Educating a new
generation of creative scientists encouraged to dismiss traditional barriers and synthesize ideas
from a multidisciplinary perspective will serve to enhance research across academia.

Academia may also benefit from increased collaboration with external partners such as the tech
industry, or simply take inspiration from tech practices. Adopting practices that promote
productivity and collaboration may improve cooperation of scientists from diverse fields, while
versioning, issue tracking, automation, and backup tools may improve analytic reproducibility. Decentralizing data storage, accessibility, and analytic tools so that they are no longer siloed in
individual institutions or even departments can also contribute to a culture of reproducibility by
enabling the re-analysis or integrative analysis of data. Data parasitism, despite the negative
connotation, serves to improve research efficiency, reduce waste, and lead to new discovery.
Consolidating thematically similar sources of data and interrogating why they do or do not support
the same hypotheses, re-analyzing negative data in the context of other negative data or
secondary sources, assessing the most impactful data collection that can be performed to
maximize the utility of existent data sources, and other secondary and integrative data analysis
modalities may improve replicability of biomedical research findings via contextualization and
meta-analyses.

The emergent recognition of and debate over data parasitism highlights an adjacent concern,
traditional standards for publication and the increasing recognition of the utility of reporting
“unsuccessful” experimental results and data descriptions. Reporting all results, even ones that
are not novel or exciting, is a necessary part of improving reproducibility. This saves time, money,
and effort on unnecessarily conducting analyses that other researchers have already performed,
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while also presenting the data for other researchers to critique and consider the impact of
applying different data cleaning or analytic methods. Traditional publication of even successful
results may also contribute to irreproducibility if page length and upload size limits preclude
descriptions that are in-depth enough to re-run the experiment and analysis to arrive upon the
same findings. A solution could be an entirely open-access journal with standardized data upload
and reporting formats tailored to experiment type that performs exploratory data analysis,
visualization, etc. automatically in an executable notebook. This would enable centralized data
access and straightforward comparison, and all analyses performed beyond or in modification of
the standard could automatically raise flags that demand an accompanying justification for each
change.

The importance of epistasis and interaction-centric research
Pathway and network-based analyses of genomic data are increasingly appealing ways to
represent the molecular interactions, hierarchies, and cascades that give rise to human
phenotypes as we recognize that individual variants may be less important than the joint effects
of many variants distributed across the genome. This implicitly acknowledges the importance of
epistasis in explaining the “missing heritability” of complex disease, and also emphasizes the
need to revisit heritability estimates to acknowledge the contribution of interactions between loci.
It also stresses the adjacent needs to consider higher-order interactions between variants and
gene-environmental interactions in risk prediction; the genome does not exist in isolation, and like
interactions between variants, interactions between genes and the environment may also be nonadditive and exist in the absence of main effects. Studying epistasis and adopting a more
interaction-centric approach to research in general is emblematic of embracing rather than
ignoring or rejecting the inherently interdependent, hierarchical, and complex nature of biology.
Considering the contribution of interactions may additionally produce more reproducible research
via substantiating the importance of higher-order relationships over individual variants; where
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single variant hits or the interactions between them may fail to replicate, quantifying the
cumulative risk or protection conferred by many variants may be more stable within and across
populations. Updating risk predictions for interactions between genetic and environmental
determinants of disease in a probabilistic way based on observations from many studies can
additionally allow for models that attempt to quantify uncertainty around individual and joint
parameter combinations for a more full understanding of the structure of the relationship between
variants and other risk factors.

Studying variants in terms of their greater genomic and environmental context is also necessary
for ensuring equitable access to the benefits of personalized medicine in the future. In order for
personalized medicine to be both maximally impactful and socially just, genomic science must
address its diversity problem and focus heavily on the importance and challenges of studying
non-Caucasian populations, especially considering the inequitable distribution of research
resources across populations and the impact of globalization and the increasingly multiracial
world. However, the current standard of substantiating GWAS findings in a replication cohort of
the same ancestral background may hamper the ability to request funding or justify performing
research in other populations and thereby serve to perpetuate the currently unjust state of
research. Thoroughly exploring how differences in risk associated with variants or their
interactions may be dependent upon population-specific genetic architecture or environmental
exposures is necessary for truly quantifying the effect of variation at a given locus, and will
require complementary work across many populations, particularly those with greater admixture.
Estimates of variant risk derived in one population cannot be used to predict risk in another,
although performing analyses across many populations can of course lend robustness to findings
that replicate, and provide informative contextual clues as to why others may not. Analyses of
interactions, networks, and pathways rather than individual loci may become the new paradigm
for exploring genomic data in a future that embraces population differences as informative rather
than inconvenient.
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Conclusions
The increasing interconnectedness of the biomedical sciences, both in terms of the
multidisciplinary expertise required for conducting modern research and the imperative to
consider joint effects at multiple levels of complexity, can facilitate a more robust, cooperative,
and translational research future. It is possible that all the necessary computational and
methodological advances necessary to truly understand human genetic variation have already
been made across diverse fields, and that we are on the cusp of substantial and immediate
benefit to human health and personalized medicine upon context-specific translation of these
tools and ideas. The rapid influx of genomic and other biomedical data should be welcomed as
resources that will enable and empower researchers to explore complex systems in
unprecedented depth to truly impact health and medicine. Although there remain many serious
barriers to improving the reproducibility of interaction analyses and scientific reproducibility in
general, we should be inspired rather than daunted by this complexity and the exciting research
opportunities it provides.
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APPENDIX
Supplemental Tables and Figures, Chapter 3
Supplemental table 1. Data set simulation parameters. Minor allele frequencies and penetrance
tables used to generate balanced case-control ratio data sets of size 10,000. Heritability = 0.005
and prevalence = 0.1 constant across all simulations.

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

Scenario 1
0.1
0.1
0.205
0.182
0.102
0.176
0.282
0.640
0.219
0.110
0.248

Scenario 2
0.2
0.1
0.208 0.190 0.148
0.164 0.244 0.433
0.202 0.198 0.192

Scenario 3
0.2
0.2
0.189 0.213 0.273
0.225 0.166 0.066
0.173 0.266 0.094

Scenario 4
0.3
0.1
0.211
0.194
0.166
0.153
0.227
0.334
0.151
0.186
0.532

Scenario 5
0.3
0.2
0.201 0.203 0.182
0.203 0.201 0.181
0.166 0.146 0.639

Scenario 6
0.3
0.3
0.220 0.172 0.223
0.191 0.220 0.157
0.134 0.260 0.276

Scenario 7
0.4
0.1
0.188
0.199
0.228
0.253
0.203
0.072
0.180
0.212
0.208

Scenario 8
0.4
0.2
0.221 0.191 0.180
0.157 0.212 0.260
0.206 0.248 0.040

Scenario 9
0.4
0.3
0.202 0.218 0.143
0.204 0.175 0.267
0.172 0.221 0.198

Scenario 10
0.4
0.4
0.159
0.228
0.209
0.211
0.186
0.217
0.259
0.179
0.130

Scenario 11
0.5
0.1
0.205 0.207 0.180
0.170 0.177 0.277
0.296 0.026 0.452

Scenario 12
0.5
0.2
0.190 0.192 0.225
0.216 0.224 0.136
0.229 0.130 0.310

Scenario 13
0.5
0.3
0.185
0.188
0.239
0.233
0.207
0.152
0.124
0.234
0.208

Scenario 14
0.5
0.4
0.154 0.204 0.238
0.246 0.195 0.164
0.167 0.205 0.222

Scenario 15
0.5
0.5
0.224 0.279 0.219
0.220 0.187 0.205
0.236 0.247 0.170
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Supplemental table 2. Data set simulation parameters. Minor allele frequencies and penetrance
tables used to generate balanced case-control ratio data sets of size 10,000. Heritability = 0.005
and prevalence = 0.02 constant across all simulations.

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

SNP1 MAF:
SNP2 MAF:
Penetrance:

Scenario 1
0.1
0.1
0.022
0.013
0.008
0.013
0.052
0.035
0.016
0.008
0.709

Scenario 2
0.2
0.1
0.023
0.016
0.002
0.007
0.036
0.010
0.022
0.016
0.029

Scenario 3
0.2
0.2
0.016
0.027
0.019
0.028
0.006
0.006
0.012
0.016
0.183

Scenario 4
0.3
0.1
0.024
0.017
0.009
0.001
0.031
0.069
0.022
0.021
0.005

Scenario 5
0.3
0.2
0.017
0.027
0.002
0.025
0.007
0.056
0.023
0.017
0.016

Scenario 6
0.3
0.3
0.017
0.027
0.003
0.027
0.008
0.039
0.003
0.039
0.023

Scenario 7
0.4
0.1
0.018
0.024
0.011
0.028
0.009
0.058
0.026
0.010
0.034

Scenario 8
0.4
0.2
0.019
0.025
0.006
0.025
0.008
0.047
0.003
0.031
0.023

Scenario 9
0.4
0.3
0.031
0.012
0.009
0.010
0.028
0.023
0.010
0.012
0.067

Scenario 10
0.4
0.4
0.005
0.028
0.029
0.027
0.019
0.007
0.031
0.005
0.039

Scenario 11
0.5
0.1
0.022
0.023
0.012
0.012
0.006
0.056
0.023
0.014
0.030

Scenario 12
0.5
0.2
0.025
0.024
0.008
0.010
0.013
0.045
0.025
0.020
0.017

Scenario 13
0.5
0.3
0.006
0.023
0.029
0.036
0.019
0.006
0.022
0.010
0.040

Scenario 14
0.5
0.4
0.041
0.012
0.014
0.010
0.026
0.019
0.004
0.020
0.036

Scenario 15
0.5
0.5
0.045
0.004
0.026
0.013
0.026
0.016
0.009
0.025
0.021
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Supplemental Table 3. Summary of performance measures across minor allele frequency
combinations, prevalence = 0.5, n = 10000.

Measure,
Model
Scenario
SNP1 MAF: 0.1
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.1
SNP1 MAF: 0.3
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.1
SNP1 MAF: 0.4
SNP2 MAF: 0.2
SNP1 MAF: 0.4
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.1
SNP1 MAF: 0.5
SNP2 MAF: 0.2
SNP1 MAF: 0.5
SNP2 MAF: 0.3
SNP1 MAF: 0.5
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.5

Sens,
without
int

Sens,
with int

Spec,
without
int

Spec,
with int

PPV,
without
int

PPV,
with int

NPV,
without
int

NPV,
with
int

8.60e-06

1.75e-04

N.S.

N.S.

4.12e-10

4.06e-09

N.S.

N.S.

6.92e-06

2.47e-05

N.S.

2.68e-02

3.03e-20

9.55e-22

4.35e-02

N.S.

9.27e-09

3.03e-05

N.S.

N.S.

5.01e-14

5.92e-15

2.73e-02

N.S.

2.27e-06

1.20e-03

N.S.

N.S.

1.74e-14

2.81e-13

N.S.

N.S.

6.65e-17

4.12e-10

N.S.

N.S.

1.48e-21

1.07e-19

N.S.

1.46e-02

5.56e-06

2.10e-07

N.S.

N.S.

1.75e-09

3.07e-16

N.S.

N.S.

8.97e-07

4.54e-05

N.S.

N.S.

7.73e-13

1.00e-13

N.S.

N.S.

2.66e-03

5.54e-05

N.S.

N.S.

2.86e-15

2.07e-17

N.S.

N.S.

4.38e-07

4.06e-09

N.S.

N.S.

1.44e-11

1.75e-09

N.S.

N.S.

3.63e-04

2.11e-04

N.S.

N.S.

1.97e-11

1.63e-05

N.S.

N.S.

5.57e-07

7.08e-07

N.S.

N.S.

1.43e-16

6.65e-17

N.S.

7.45e-03

4.06e-09

5.93e-08

N.S.

N.S.

3.95e-22

1.62e-19

N.S.

N.S.

1.27e-07

2.32e-09

N.S.

N.S.

4.00e-12

1.69e-10

N.S.

N.S.

8.97e-07

1.13e-06

N.S.

N.S.

1.43e-16

1.37e-15

3.08e-02

N.S.

4.06e-09

3.71e-05

N.S.

N.S.

5.53e-13

2.89e-12

N.S.

N.S.
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Supplemental Table 4. Summary of performance measures across minor allele frequency
combinations, prevalence = 0.1, n = 10000.

Measure,
Model
Scenario
SNP1 MAF: 0.1
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.1
SNP1 MAF: 0.3
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.1
SNP1 MAF: 0.4
SNP2 MAF: 0.2
SNP1 MAF: 0.4
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.1
SNP1 MAF: 0.5
SNP2 MAF: 0.2
SNP1 MAF: 0.5
SNP2 MAF: 0.3
SNP1 MAF: 0.5
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.5

Sens,
without
int

Sens,
with int

Spec,
without
int

Spec,
with int

PPV,
without
int

PPV,
with int

NPV,
without
int

NPV,
with
int

6.75e-05

2.10e-07

N.S.

N.S.

1.74e-14

1.97e-11

N.S.

N.S.

2.08e-08

1.22e-08

4.86e-02

N.S.

1.97e-11

6.50e-16

N.S.

N.S.

1.07e-05

1.32e-05

N.S.

N.S.

1.97e-11

3.07e-16

N.S.

N.S.

3.07e-09

1.74e-14

N.S.

N.S.

3.07e-16

1.40e-17

N.S.

N.S.

5.57e-07

5.53e-10

N.S.

N.S.

4.47e-16

1.22e-14

N.S.

4.35e-02

1.07e-05

8.20e-05

5.21e-03

N.S.

6.15e-22

9.25e-11

N.S.

N.S.

2.71e-08

2.47e-05

N.S.

N.S.

1.22e-14

1.37e-15

N.S.

N.S.

8.60e-06

1.07e-05

N.S.

N.S.

5.92e-15

5.53e-13

N.S.

3.88e-02

9.87e-10

9.87e-10

N.S.

N.S.

5.53e-13

6.33e-18

N.S.

N.S.

3.71e-05

5.53e-10

N.S.

N.S.

5.02e-11

9.42e-18

N.S.

N.S.

9.25e-11

5.53e-10

N.S.

N.S.

7.73e-13

4.52e-17

N.S.

N.S.

5.54e-05

2.27e-06

N.S.

N.S.

1.22e-14

3.03e-20

1.46e-02

N.S.

1.32e-05

3.07e-10

N.S.

N.S.

2.27e-06

1.22e-08

N.S.

N.S.

6.75e-05

5.57e-07

N.S.

N.S.

9.25e-11

2.08e-08

N.S.

N.S.

1.22e-14

5.53e-12

N.S.

N.S.

6.50e-16

7.10e-14

N.S.

N.S.
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Supplemental Table 5. Summary of performance measures across minor allele frequency
combinations, prevalence = 0.02, n = 10000.

Measure,
Model
Scenario
SNP1 MAF: 0.1
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.1
SNP1 MAF: 0.2
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.1
SNP1 MAF: 0.3
SNP2 MAF: 0.2
SNP1 MAF: 0.3
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.1
SNP1 MAF: 0.4
SNP2 MAF: 0.2
SNP1 MAF: 0.4
SNP2 MAF: 0.3
SNP1 MAF: 0.4
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.1
SNP1 MAF: 0.5
SNP2 MAF: 0.2
SNP1 MAF: 0.5
SNP2 MAF: 0.3
SNP1 MAF: 0.5
SNP2 MAF: 0.4
SNP1 MAF: 0.5
SNP2 MAF: 0.5

Sens,
without
int

Sens,
with int

Spec,
without
int

Spec,
with int

PPV,
without
int

PPV,
with int

NPV,
without
int

NPV,
with
int

2.28e-10

9.25e-11

4.20e-03

1.12e-02

1.40e-17

1.98e-20

1.46e-02

1.46e-02

1.80e-06

1.75e-09

1.03e-02

N.S.

1.25e-10

4.21e-24

N.S.

N.S.

7.10e-14

1.05e-11

N.S.

1.70e-02

9.27e-09

3.72e-19

N.S.

N.S.

3.07e-09

9.27e-09

N.S.

5.58e-03

9.25e-11

1.98e-20

N.S.

4.35e-02

1.13e-06

3.07e-09

4.09e-03

N.S.

2.32e-09

1.66e-24

N.S.

N.S.

1.32e-09

5.53e-12

3.16e-02

N.S.

1.25e-10

2.10e-16

N.S.

N.S.

1.08e-12

4.12e-10

N.S.

3.73e-02

3.52e-08

3.19e-27

N.S.

N.S.

4.12e-10

7.40e-10

1.80e-02

N.S.

8.49e-15

1.98e-15

N.S.

N.S.

7.73e-13

1.43e-16

1.07e-02

4.93e-03

7.67e-08

3.95e-22

N.S.

N.S.

5.46e-21

1.08e-12

N.S.

N.S.

2.89e-12

1.22e-14

N.S.

N.S.

5.36e-09

6.14e-04

N.S.

N.S.

6.82e-11

1.97e-11

N.S.

N.S.

4.38e-07

4.06e-09

N.S.

N.S.

2.69e-07

4.52e-17

N.S.

N.S.

7.06e-09

4.58e-08

N.S.

N.S.

7.73e-13

8.44e-19

N.S.

N.S.

1.43e-06

5.36e-09

N.S.

N.S.

1.44e-11

5.46e-21

4.35e-02

N.S.

5.02e-11

5.57e-07

N.S.

2.75e-05

3.44e-07

1.62e-19

N.S.

N.S.
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Supplemental Figure 1. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 1, prevalence = 0.5, n = 2000
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Supplemental Figure 2. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 2, prevalence = 0.5, n = 2000
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Supplemental Figure 3. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 3, prevalence = 0.5, n = 2000
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Supplemental Figure 4. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 4, prevalence = 0.5, n = 2000
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Supplemental Figure 5. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 5, prevalence = 0.5, n = 2000
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Supplemental Figure 6. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 6, prevalence = 0.5, n = 2000
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Supplemental Figure 7. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 7, prevalence = 0.5, n = 2000
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Supplemental Figure 8. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 8, prevalence = 0.5, n = 2000

72

Supplemental Figure 9. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 9, prevalence = 0.5, n = 2000
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Supplemental Figure 10. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 10, prevalence = 0.5, n = 2000
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Supplemental Figure 11. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 11, prevalence = 0.5, n = 2000

75

Supplemental Figure 12. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 12, prevalence = 0.5, n = 2000
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Supplemental Figure 13. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 13, prevalence = 0.5, n = 2000
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Supplemental Figure 14. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 14, prevalence = 0.5, n = 2000
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Supplemental Figure 15. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 15, prevalence = 0.5, n = 2000
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Supplemental Figure 16. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 1, prevalence = 0.5, n = 10000
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Supplemental Figure 17. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 2, prevalence = 0.5, n = 10000
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Supplemental Figure 18. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 3, prevalence = 0.5, n = 10000
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Supplemental Figure 19. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 4, prevalence = 0.5, n = 10000
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Supplemental Figure 20. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 5, prevalence = 0.5, n = 10000
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Supplemental Figure 21. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 6, prevalence = 0.5, n = 10000
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Supplemental Figure 22. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 7, prevalence = 0.5, n = 10000
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Supplemental Figure 23. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 8, prevalence = 0.5, n = 10000
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Supplemental Figure 24. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 9, prevalence = 0.5, n = 10000
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Supplemental Figure 25. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 10, prevalence = 0.5, n = 10000
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Supplemental Figure 26. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 11, prevalence = 0.5, n = 10000
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Supplemental Figure 27. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 12, prevalence = 0.5, n = 10000
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Supplemental Figure 28. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 13, prevalence = 0.5, n = 10000

92

Supplemental Figure 29. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 14, prevalence = 0.5, n = 10000
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Supplemental Figure 30. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 15, prevalence = 0.5, n = 10000
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Supplemental Figure 31. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 1, prevalence = 0.1, n = 10000
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Supplemental Figure 32. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 2, prevalence = 0.1, n = 10000
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Supplemental Figure 33. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 3, prevalence = 0.1, n = 10000
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Supplemental Figure 34. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 4, prevalence = 0.1, n = 10000
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Supplemental Figure 35. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 5, prevalence = 0.1, n = 10000
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Supplemental Figure 36. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 6, prevalence = 0.1, n = 10000
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Supplemental Figure 37. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 7, prevalence = 0.1, n = 10000
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Supplemental Figure 38. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 8, prevalence = 0.1, n = 10000
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Supplemental Figure 39. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 9, prevalence = 0.1, n = 10000

103

Supplemental Figure 40. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 10, prevalence = 0.1, n = 10000
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Supplemental Figure 41. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 11, prevalence = 0.1, n = 10000
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Supplemental Figure 42. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 12, prevalence = 0.1, n = 10000
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Supplemental Figure 43. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 13, prevalence = 0.1, n = 10000
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Supplemental Figure 44. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 14, prevalence = 0.1, n = 10000

108

Supplemental Figure 45. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 15, prevalence = 0.1, n = 10000
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Supplemental Figure 46. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 1, prevalence = 0.02, n = 10000
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Supplemental Figure 47. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 2, prevalence = 0.02, n = 10000
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Supplemental Figure 48. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 3, prevalence = 0.02, n = 10000
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Supplemental Figure 49. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 4, prevalence = 0.02, n = 10000
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Supplemental Figure 50. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 5, prevalence = 0.02, n = 10000
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Supplemental Figure 51. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 6, prevalence = 0.02, n = 10000
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Supplemental Figure 52. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 7, prevalence = 0.02, n = 10000
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Supplemental Figure 53. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 8, prevalence = 0.02, n = 10000
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Supplemental Figure 54. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 9, prevalence = 0.02, n = 10000
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Supplemental Figure 55. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 10, prevalence = 0.02, n = 10000
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Supplemental Figure 56. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 11, prevalence = 0.02, n = 10000
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Supplemental Figure 57. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 12, prevalence = 0.02, n = 10000
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Supplemental Figure 58. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 13, prevalence = 0.02, n = 10000
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Supplemental Figure 59. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 14, prevalence = 0.02, n = 10000
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Supplemental Figure 60. Consistency of training and testing performance measures for models
with and without the interaction term, comparing a traditional cross validation procedure to PICV.
Experimental scenario 15, prevalence = 0.02, n = 10000
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Supplemental Tables and Figures, Chapter 4
Supplemental table 1. Counts and mean values of the phenotype by interaction genotype
among individuals included in the simulated analysis, the real analysis, and exclusively in the real
analysis but not the simulated analysis. Interaction genotypes listed refer to minor allele counts
for rs2192872 and rs8068517, respectively (e.g. 01 refers to the interaction genotype of
individuals with 0 copies of the minor allele for rs2192872 and 1 copy of the minor allele for
rs8068517).
rs2192872:
rs8068517
interaction
genotype

00

01

02

10

11

12

20

21

22

Simulated

0.942

0.922

0.909

0.938

0.910

0.916

0.874

0.916

0.909

(n = 680)

(1)

(19)

(76)

(5)

(42)

(238)

(2)

(57)

(240)

0.942

0.927

0.910

0.938

0.907

0.914

0.900

0.912

0.908

(n = 778)

(1)

(24)

(83)

(5)

(49)

(273)

(4)

(67)

(272)

Exclusively
real

N/A

0.946

0.924

N/A

0.887

0.903

0.927

0.885

0.898

(0)

(5)

(7)

(0)

(7)

(35)

(2)

(10)

(32)

Real

(n = 98)
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Supplemental figure 1. Phenotype distributions by genotype for the 680 subjects included in the
analysis of the simulated data. A. Phenotype distributions for individuals with 0, 1, or 2 copies of
the minor allele for rs2192872. B. Phenotype distributions for individuals with 0, 1, or 2 copies of
the minor allele for rs8068517 amongst those with 0 copies of the minor allele for rs2192872 [left];
1 copy [center]; 2 copies [right]. C. Phenotype distributions for individuals with 0, 1, or 2 copies of
the minor allele for rs8068517. D. Phenotype distributions for individuals with 0, 1, or 2 copies of
the minor allele for rs8068517 [left]; 1 copy [center]; 2 copies [right].
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Supplemental figure 2. Phenotype distributions by genotype for the 778 subjects included in the
analysis of the real data. A. Phenotype distributions for individuals with 0, 1, or 2 copies of the
minor allele for rs2192872. B. Phenotype distributions for individuals with 0, 1, or 2 copies of the
minor allele for rs8068517 amongst those with 0 copies of the minor allele for rs2192872 [left]; 1
copy [center]; 2 copies [right]. C. Phenotype distributions for individuals with 0, 1, or 2 copies of
the minor allele for rs8068517. D. Phenotype distributions for individuals with 0, 1, or 2 copies of
the minor allele for rs2192872 amongst those with 0 copies of the minor allele for rs8068517 [left];
1 copy [center]; 2 copies [right].
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Supplemental figure 3. Phenotype distributions by genotype for the 98 subjects exclusively
included in the analysis of the real data and not included in the analysis of the simulated data. A.
Phenotype distributions for individuals with 0, 1, or 2 copies of the minor allele for rs2192872. B.
Phenotype distributions for individuals with 0, 1, or 2 copies of the minor allele for rs8068517
amongst those with 0 copies of the minor allele for rs2192872 [left]; 1 copy [center]; 2 copies
[right]. C. Phenotype distributions for individuals with 0, 1, or 2 copies of the minor allele for
rs8068517. D. Phenotype distributions for individuals with 0, 1, or 2 copies of the minor allele for
rs2192872 amongst those with 0 copies of the minor allele for rs8068517 [left]; 1 copy [center]; 2
copies [right].
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